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ABSTRACT
Self-efficacy for Symptom Management in Adult Hematopoietic
Stem Cell Transplant Patients
Lynn L. White, PhD
University of Nebraska Medical Center, 2017
Advisor: Marlene Z. Cohen, PhD, RN, FAAN
Hematopoietic stem cell transplant (HSCT) is a treatment for hematologic cancers and other
hematologic conditions that causes severe treatment-related symptoms. The first 30 days after
HSCT, or the acute phase, is when symptoms are most intense. During this time, the ability of
patients to manage their symptoms, in collaboration with their health care providers, is crucial to
reduce the distress caused by the symptoms. Self-efficacy is the person’s confidence in their
ability to perform a behavior, such as symptom management. This body of work describes the
concept of self-efficacy for symptom management (SESM), presents an integrated literature
review on self-efficacy for symptom management in cancer patients, and presents results from
research on SESM during the acute phase of HSCT. The purpose of the longitudinal, descriptive
study was to determine changes over time and examine the relationships between SESM,
symptom distress and physical function. The meaning of SESM from the patient’s perspective
pre- and post-HSCT also was explored. The study established that significant changes occur over
time in these variables and that a relationship is present between SESM, symptom distress and
physical functional status during the acute phase of transplant. Higher SESM was associated with
less symptom distress and increased physical function. When symptom distress was highest,
patients felt their worst and their self-efficacy was low, which influences how symptoms are
managed, and affects outcomes such as functional status, hospital length of stay and overall
quality of life. Assessment of SESM early in the treatment process, followed by patient-centered
interventions to enhance SESM, will allow patients to manage their symptoms effectively and
improve patient outcomes. The information presented here provides a foundation for future
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research and development of nursing interventions to enhance a person’s SESM during the acute
phase of HSCT.
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CHAPTER 1: INTRODUCTION
Background
Hematopoietic stem cell transplant (HSCT), also known as bone marrow or stem cell
transplant, is an intensive treatment for hematological cancers such as multiple myeloma,
lymphoma, and leukemia and other hematological conditions such as sickle cell disease or
aplastic anemia. This treatment offers the potential for disease remission, or for some patients, a
cure. A person can receive donor stem cells from themselves (autologous) or donor stem cells
from a sibling or unrelated donor (allogeneic). The donor type chosen is dictated by diagnosis,
stage, and donor availability. The numbers of HSCT in the United States is increasing as more
umbilical cord blood and haploidentical, or half-matched, donors are used (D'Souza, Pasquini, &
X., 2016). Researchers are striving to increase survival, reduce complications, and treat persons
who previously would not have been candidates for this aggressive treatment due to their age or
other chronic illnesses or comorbidities (D'Souza et al., 2016).
The HSCT process consists of several steps including evaluation of the recipient, donor
testing and selection, conditioning chemotherapy and for some, radiation, followed by the
infusion of stem cells (National Marrow Donor Program, 2017). Before the transplant, the
recipient undergoes an evaluation that includes, but is not limited to, a physical exam, lung and
cardiac function studies, laboratory testing, and a psychological exam. The patient is admitted to
the hospital before starting the preparatory or conditioning regimen. The conditioning regimen
consists of high dose chemotherapy, and potential total body irradiation, depending on the type of
disease. The conditioning regimen lasts from a few hours to seven days, based on the type of
transplant and conditioning regimen. After the conditioning regimen is complete, the stem cells
are infused to the patient via an intravenous line. The nadir, or time when the blood counts are at
the lowest, occurs at 7-14 days after the conditioning regimen (Anderson et al., 2007).
Engraftment follows, which is when the stem cells begin to produce red cells, white cells, and
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platelets, and recovery of the immune system. The risk for complications is especially high during
the nadir and prior to engraftment, and symptoms tend to peak in severity and cause the most
distress (Anderson 2007; Bevans 2008). Patients are discharged from the acute setting after blood
counts have recovered and post-HSCT complications have resolved (Bevans 2008).
The phase up to 30 days after transplant is when the greatest risk for complications exists
and physical functioning and overall quality of life (QOL) are at their lowest levels (Bevans,
2010; Pidala, Anasetti, & Jim, 2009). This time is also when treatment-related symptoms are at
their peak, causing distress and impacting functional status and outcomes. Symptoms occur in
clusters, which adds to the severity and distress. Management of symptoms during this time is of
vital importance. However, this time is also when patients are feeling their worst and may not
have the ability to manage their symptoms or treatment regimen. Some patients are discharged
from the acute care setting before this point and are required to self-manage their symptoms and
post-treatment regimens along with their non-professional caregiver (Oguz, Akin, & Durna,
2014).
Conceptual definition of key concepts
Symptom distress
Symptoms are an indication of a condition that is different from normal and are important
cues that bring problems to the attention of the caregiver (Rhodes & Watson, 1987). Because of
the subjective nature of symptoms, they become known when the patient reports their presence.
Distress is a global term that represents an extensive range of emotional concerns that patients
experience and may be less stigmatizing or embarrassing to patients than using words like
emotional or psychiatric (Holland et al., 2013; Rhodes & Watson, 1987).
Rhodes and Watson (1987) described the meaning of symptom distress as "physical or
mental anguish or suffering that results from the experience of symptom occurrence and/or
perception of feeling states" (p. 243). Lenz, Pugh, Milligan, Gift, and Suppe (1997) discuss
symptom distress within the Theory of Unpleasant Symptoms context as the degree to which the
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symptoms bother the person. Another definition provided by Holland et al. (2013) in the National
Comprehensive Cancer Network (NCCN) guidelines is that distress is the psychological,
emotional, social, or spiritual concern caused by symptoms that may "interfere with the ability to
cope effectively with cancer" (p. 192). Terms that are related to distress but different include
bother, burden, occurrence, experience, awareness, and perception (Goodell & Nail, 2005; Hsiao,
Loescher, & Moore, 2007). Symptom distress can be related to the person's disease or treatment
(Goodell & Nail, 2005).
A combination of intensity, frequency, and QOL are components of the symptom
experience that may lead to distress (Armstrong, 2003; Goodell & Nail, 2005). The most intense
or frequently occurring symptoms are not always the most distressing to the patient (McClement,
Woodgate, & Degner, 1997). Examples of distressing symptoms in oncology and transplant
patients are prevalent in the literature and include fatigue, worry (anxiety), depression, lack of
appetite, pain, sleep disturbances, diarrhea or bowel changes, dry mouth, weakness, and others
(Anderson et al., 2007; Badger, Segrin, & Meek, 2011; Bevans, Mitchell, & Marden, 2008;
Hefner et al., 2014; Larsen, Nordström, Björkstrand, Ljungman, & Gardule, 2003). Anxiety or
depression can influence the amount of distress a person feels from their symptoms (Lenz et al.,
1997). Other concerns such as prognosis, disease treatment, and side effects, social or financial
concerns or other issues impacts levels of symptom distress (Holland et al., 2013). The most
distressing symptoms may not be the most meaningful, and meanings associated with symptoms
may impact physical and psychological health (Armstrong, 2003). The perception of the intensity
of the symptom may be influenced by the perceived ominous meaning of the symptom (Dodd et
al., 2001). For example, a headache may have a different meaning in the healthy individual as
opposed to an individual who has just completed intensive treatment for brain cancer.
Management of Symptoms and Symptom distress
The relationship that symptom distress has to patient outcomes in the HSCT population
has been well-documented and includes higher anxiety and depression, decreased physical
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functional status, and QOL (Bevans et al., 2014; Ransom, Jacobsen, & Booth-Jones, 2006). The
presence of symptom distress has been shown to be a predictor of survival in those with cancer
and as a prognostic variable of long-term survival in HSCT (Bevans et al., 2014; McClement et
al., 1997). HSCT survivors with high symptom distress had impairments in physical health,
significantly lower mental health (p<.001) and lower health-related QOL (Bevans et al., 2014).
Allogeneic and autologous HSCT patients have been found to have similar rates and quality of
psychological distress (Hefner et al., 2014). HSCT patients with symptom distress are more likely
to be non-adherent to treatment, have sleep disturbances, and anxiety and depression, which can
lead to increased hospitalizations (Bevans et al., 2011; Rischer, Scherwath, Zander, Koch, &
Schulz-Kindermann, 2009). Management of symptoms impacts treatment-related costs of health,
hospitalizations and use of the health care system (Gapstur, 2007; Ryan & Sawin, 2009). Selfmanagement of symptoms has been shown to optimize outcomes and influence QOL and survival
in patients with cancer (Hoffman, 2013; McCorkle et al., 2011). Management of symptoms is
vital to the symptom experience, both for cancer patients and those who receive HSCT.
Self-efficacy
Self-efficacy is a person’s belief or confidence in their ability to implement behaviors to
achieve an outcome, such as management of symptoms (Hoffman, 2013). Unless people believe
they can have an influence on results, they are not motivated to act (Bandura, 2001). Knowledge
and skills of disease care are needed for self-efficacy along with cognitive and affective
processes, motivation, confidence, competence, and awareness (Hoffman, 2013; Ryan & Sawin,
2009; White et al., in press). Self-efficacy affects self-management of symptoms as the person’s
perception of their ability to implement interventions will have an impact on the desired outcomes
(Hoffman, 2013). As the person's level of performance of self-management behaviors increases,
the person's perceived self-efficacy increases and patients are empowered to change behaviors
(Hoffman, 2013).
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Self-efficacy for symptom management
Self-efficacy for symptom management (SESM) is the ability to implement behaviors to
prevent, recognize, and relieve symptoms in patients with cancer or undergoing HSCT (White et
al., in press). High self-efficacy leads to effective self-management behaviors, and have been
shown to improve symptom management in chronic illness, which reduces health care
expenditures and utilization of health care services (Novak, Costantini, Schneider, & Beanlands,
2013). High self-efficacy in HSCT patients may lead to more effective symptom management,
which in turn would decrease symptom distress and improve outcomes (Bevans et al., 2014).
Theoretical Foundations
The theoretical foundation for this body of work was drawn from a combination of
theories by Bandura (1997), Hoffman (2013), and Lenz et al. (1997) (Figure 1). These three
theories are based on the concepts of self-efficacy, symptom distress, and self-management of
symptoms. Bandura’s Self-efficacy theory states that self-efficacy is what people believe they can
do under various circumstances and that people act when they believe they can influence results
(Bandura, 1986, 2001). Self-efficacy is the ability to perform a desired behavior and must be
domain specific, such as symptom management. If persons perceive they are ineffective, they
approach intimidating situations with more anxiety (Bandura, 1986). Components that may
influence symptom distress are situational, psychological, and physiologic factors (Lenz et al.,
1997). A relationship between self-efficacy and the ability to manage symptoms has been shown
(Hoffman, 2013). Self-efficacy impacts functional status and quality of life and reduced
symptoms impact outcomes such as health status, quality of life and cost of health (Hoffman,
2013; Lenz et al., 1997).
Symptoms are a sign that there is a change in health, and are a critical component of
health care, especially for cancer and HSCT patients. The Theory of Unpleasant Symptoms (Lenz
et al., 1997) conceptualizes symptoms as a multidimensional experience, where symptoms occur
alone or in clusters and can potentiate each other. Symptom distress includes physical and mental
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suffering or discomfort, awareness of symptom importance, the need to change actions,
frequency, intensity, quality, and duration of symptoms (Hsiao et al., 2007; Lenz et al., 1997).
Adverse outcomes from symptom distress include readmission to the hospital after discharge,
decreased physical functional status and decreased QOL (Bevans et al., 2014; Novak et al., 2013).
The Theory of Symptom Self-management blends the concept of self-efficacy with
symptom management to provide a framework for efficacy-enhancing interventions for patients
with cancer (Hoffman, 2013). The outcomes of this theory are performance based, both functional
and cognitive, from a person’s symptom self-management behaviors (Hoffman, 2013). These
three theories provide a conceptual framework that includes self-efficacy, the symptom
experience, and self-efficacy for symptom management.
Significance
Self-efficacy plays a critical role in the self-management of symptoms. Memory and
concentration impairments are adverse effects of high-dose chemotherapy received during HSCT
and have the potential to impact self-efficacy (Wu et al., 2012). Wu et al. (2012) found that better
cognitive functioning was associated with improved self-efficacy for symptom management,
which was then associated with less depressed mood, reduced anxiety, and better QOL. Selfefficacy is associated with decreased symptoms and is a significant predictor of emotional and
physical well-being and QOL after transplant (Bergkvist et al., 2015; Hochhausen et al., 2007;
Wu et al., 2012). These studies, while different in their objectives, show that self-efficacy is
important in the symptom management for HSCT patients. None of the studies described here,
however, evaluated self-efficacy and its relationship to management of symptom distress during
the acute phase of HSCT when symptom distress is at its highest levels. Liang et al. (2016) found
that SESM impacted the relationship between symptom distress and QOL in breast cancer
patients. While no studies were found linking self-efficacy specifically with symptom distress in
HSCT patients, it follows that the decrease in symptom occurrence, depression, and anxiety, and
the increase in QOL found with greater self-efficacy would be associated with decreased
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symptom distress. Despite findings that symptom distress affects patient outcomes, the literature
shows that targeted interventions are still lacking (Braamse et al., 2014).
Symptom management is a critical area for clinical research outcomes as identified by the
Oncology Nursing Society and by the National Institute for Nursing Research (Knobf et al., 2015;
National Institute of Nursing Research, 2016). These priority areas include studies of factors that
influence the management of symptoms and contribute to the design of personalized
interventions.
Research Question
While there is research published about symptom distress and outcomes in HSCT, very
little research has examined self-efficacy and no research is available regarding interventions to
facilitate self-efficacy in this population. The relationship between self-efficacy and symptom
distress in HSCT patients is not known. Research to identify needs of the HSCT patient regarding
self-efficacy to improve symptom management during the acute phase of HSCT has the potential
for development of patient-centered interventions. Facilitation of self-efficacy may enable
patients to increase engagement in managing their symptoms and lead to improved outcomes.
Purpose and Aims
The purpose of this study was to describe the changes over time and relationships
between SESM, symptom distress and the outcomes of physical function and length of stay
during the acute phase, or 30 days, post-HSCT. The specific aims were:
1. Explore the concept of SESM from the patient’s perspective at baseline and 30 days.
2. Determine the changes over time in SESM, symptom distress, and physical function.
3. Examine the relationships among SESM, symptom distress, and physical function.
4. Determine if the relationships among SESM and length of stay, readmission rates, and
functional status varies depending on the level of symptom distress.
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Summary
Four chapters are presented here to contribute to the understanding of SESM in adult
patients with cancer and HSCT recipients. Chapter II analyzes the concept of SESM in cancer
patients. Because of the scarcity of literature on SESM in HSCT patients, the concept analysis
focused on adult patients with cancer. Chapter III provides an integrative review on SESM.
Again, due to the scarcity of literature on SESM in HSCT patients, the review was broadened to
include adult patients with cancer. Chapter IV reports on the relationships of SESM, symptom
distress and outcomes in the acute phase following HSCT. Chapter V describes the meaning of
SESM from the patient’s perspective during their HSCT experience. Chapter VI provides a
synthesis of the previous content to inform nursing practice on SESM in adult HSCT patients and
addresses future steps for nursing practice and research opportunities to enhance SESM in this
patient population.
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Figure 1: Conceptual Model of Self-efficacy for Symptom Management in the Stem Cell
Transplant Patient
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CHAPTER II: Manuscript 1

Perceived Self-efficacy for Symptom Management in Cancer Patients:
A Concept Analysis
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Abstract
Background: Perceived self-efficacy (PSE) for symptom management plays a key role in
outcomes for cancer patients such as quality of life, functional status, symptom distress and health
care utilization. Greater PSE for symptom management predicts improved performance outcomes
including functional health status, cognitive functioning, and disease status. Definition of the
concept is necessary for use in research and to guide development of interventions to facilitate
PSE for symptom management in cancer patients.
Objective: This analysis will describe the concept of PSE for symptom management in cancer
patients.
Methods: A database search was performed for related publications from 2006-2016.
Publications considered to be landmark works that informed the analysis published prior to 2006
were included.
Findings: Defining attributes of PSE for symptom management are: cognitive processes,
affective processes, motivation, confidence, competence, and awareness. Antecedents identified
were presence of symptoms, performance accomplishment, verbal persuasion and presence of
threat or fear. Consequences of the concept include symptom relief, health status, cost of care,
quality of life and behavior performance. Clarification of concept of PSE for symptom
management will accelerate the progress of self-management research and allow for comparison
of research data and intervention development.
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Implications for Practice
•

The concept of perceived self-efficacy (PSE) for symptom management in cancer
patients is important as persons with cancer are expected to self-manage symptoms but
few have the ability to do so.

•

The concept of perceived self-efficacy for symptom management in cancer patients has
not been analyzed in nursing literature.

•

Patients with high perceived self-efficacy for symptom management have the potential
for improved outcomes such as quality of life, functional status, and symptom distress.

•

Nurses are positioned to help patients to increase self-efficacy for symptom management
by teaching patient’s behaviors for managing symptoms.
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Background
The purpose of a concept analysis is to clarify concepts by examining their structure and
function and to expand the body of nursing knowledge (Walker & Avant, 2011). The concept of
perceived self-efficacy (PSE) for symptom management in cancer patients is important as persons
with cancer are expected to self-manage symptoms but few can do so (Hoffman, 2013). The
concept of PSE for symptom management includes both PSE and symptom management.
Self-efficacy is a key component of self-management of symptoms and is vital for
implementation of the behaviors needed for self-management of symptoms. People are motivated
to act only when they believe they can influence results (Bandura, 2001). Studies have shown that
self-efficacy positively influences self-management behavior and is linked to higher quality of
life (QOL) and improvements in health status including decreased physical and psychological
symptoms (Lorig & Holman, 2003; Phillips & McAuley, 2013; Porter, Keefe, Garst, McBride, &
Baucom, 2008; Torbit, Albiani, Crangle, Latini, & Hart, 2015).
Symptom management is a key component of nursing and cancer care (Armstrong,
2014). Cancer patients’ symptoms are frequently occurring, severe, occur in clusters (two or more
symptoms co-occurring) and lead to symptom burden and/or distress (Barsevick, 2007; Beck,
Towsley, Caserta, Lindau, & Dudley, 2009). As cancer survivors live longer, symptom
management becomes important for improving health outcomes, increasing QOL, improving
functional status, and decreasing demand for health care services; all decreasing the cost of care
(Ryan & Sawin, 2009). Self-management of symptoms optimizes outcomes and influences QOL
and survival in patients with cancer (McCorkle et al., 2011). The outcomes of unmanaged
symptoms include increased symptom distress and poor prognosis along with decreased QOL,
functional status and survival (Gapstur, 2007).
The Oncology Nursing Society Research Agenda identified symptom management and
self-management as priorities (Knobf et al., 2015). The National Institute for Nursing Research
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also identified symptom science and self-management as priority research areas (National
Institute for Nursing Research, 2016). Conceptual clarity will aid in these endeavors.
Purpose
This concept analysis defines and clarifies the concept of PSE for symptom management
in cancer patients. Analysis of this concept will allow for conceptual clarity in research and aid in
developing interventions to enhance self-efficacy for symptom management.
Data sources
‘Self-efficacy’, ‘perceived self-efficacy’, ‘symptom management’, and ‘cancer’ were
used to search several data bases: CINAHL, Google Scholar, PubMed, MEDLINE and
PsycINFO. Inclusion criteria were literature that related to PSE, self-efficacy, and symptom
management in adult cancer patients, and published in English between 2006-2016. Exclusion
criteria were duplicate publications; topics not directly related to self-efficacy and symptom
management or adults with cancer. A manual search of references identified additional
publications. Landmark publications published prior to 2006 that informed the concept analysis
were included. Of the 183 titles and abstracts reviewed, 55 met inclusion criteria or were
landmark publications. A concept analysis combining self-efficacy and symptom management
has not been published.
Methods
Walker and Avant’s (2011) method was used to determine the antecedents, defining
attributes and consequences of this concept. PSE and symptom management have been described
previously as individual concepts (see publications in Table 1 and 2) but have not been analyzed
together. The attributes, antecedents, and consequences from the individual concept analysis of
PSE and symptom management were analyzed and synthesized with data gathered from the
literature search to inform this concept analysis.

20
Results
Definitions and uses of the concept
PSE is a persons’ beliefs about their capabilities to produce effects (Bandura, 1986,
1997). Self-efficacy can be further explained as implementing behaviors that are situation or
domain specific, with outcome expectancies dependent on the context (Hoffman et al., 2009). The
concept of PSE deals with perceived ability, while other similar terms describe the management
of behaviors such as self-regulation, self-care, self-monitoring, self-management, and patient
directed monitoring (Novak, Costantini, Schneider, & Beanlands, 2013).
For cancer patients, PSE is the person’s belief in their ability to implement behaviors to
achieve a desired outcome, such as symptom management. Self-efficacy becomes important
when a person chooses a plan of action, determines the degree of effort required to achieve the
outcome, and the amount of perseverance needed to continue when it is difficult (Hoffman,
2013). Knowledge and skills are required to implement a behavior, but self-efficacy also requires
motivation, competence, and perseverance (see Table 1). As PSE increases, persons become
empowered to change behaviors (Hoffman, 2013).
Symptom management in cancer is “a dynamic and multidimensional process in which
patients intentionally and purposefully act on and interact with the perception (or previous
perception) of the symptom(s) to initiate activities or direct others to perform activities to relieve
or decrease distress from and prevent the occurrence of a symptom” (Fu, LeMone, & McDaniel,
2004, p. 68). Symptom self-management is application of strategies by an individual to relieve
symptoms (Hsiao, Moore, Insel, & Merkle, 2014). Symptom management begins with awareness,
presence of discomfort or suffering, identification, and assessment of symptoms from the
persons’ perspective (Fu et al., 2004). Symptom management includes the presence of one or
more symptoms, the symptom experience (intensity, distress, quality, temporality, appraisal), the
effectiveness of interventions and the measurement of related outcomes (Brant, 2016). Symptoms
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that occur in clusters require different methods of management. For example, pain may
exacerbate depression, anxiety, or fatigue, adding to the complexity of care.
PSE for symptom self-management is the “ability to implement situation specific
behaviors to attain established goals, expectations, or designated types of outcomes” (Hoffman,
2013, p. E19). Hoffman further defined symptom self-management as “a dynamic, self-directed
process of implementing behaviors that recognize, prevent, and relieve or decrease the timing
(frequency, duration, occurrence), intensity, distress, concurrence, and unpleasant quality from
symptoms to achieve optimal performance outcomes” (p. E19). PSE for symptom management is
the ability to implement behaviors to prevent, recognize, and relieve symptoms in cancer patients.
Defining attributes
Attributes must be present if the concept exists (Walker & Avant, 2011). The attributes of
PSE for symptom management in cancer patients are cognitive processes, affective processes,
motivation, confidence, competence, and awareness (Figure 1).
Cognitive processes. Cognitive processes involve forming ideas, setting goals, and
acting to meet them (Zulkosky, 2009). Perception of ability plays a role in learning skills,
performing competently and perseverance (Bandura, 1997). How persons perceive and evaluate
symptoms (cognitive appraisal) is a catalyst for a response (Hoffman, 2013). PSE for symptom
management requires cognitive processes to acquire knowledge, competence and confidence
related to both PSE and management of symptoms.
Affective processes. Affective processes such as feelings of anxiety, stress, or depression
influence PSE (Bandura, 1997; Mystakidou et al., 2010; Sato & Sumi, 2015). Symptom
management is influenced by affective processes as symptom awareness and decisions for
management may be altered in conditions of high emotion or distress that are present in cancer
patients at points in the disease trajectory. Emotional reactions can change thought processes and
actions and have a relationship with cognitive processes (Zulkosky, 2009). Both cognitive
processes and affective processes are needed for behavior change (Ryan & Sawin, 2009).
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Motivation. Persons’ beliefs in their efficacy affects choices they make in management
behaviors, including how much effort to expend (Bandura, 1991). Despite having the knowledge
or ability to perform behaviors, persons may choose not to act (Zulkosky, 2009). Outcome
expectancies are the person’s belief that an action will lead to a specific result and, in the case of
symptom management, includes prevention or relief of symptoms (Lev, 1997). Motivation must
be present for both PSE and symptom management.
Confidence. A characteristic of self-efficacy is confidence, which is the belief in the
ability to perform a task or behavior (Robb, 2012). PSE for managing pain, fatigue and other
symptoms is key to a person’s ability and competence to handle challenging situations.
Confidence impacts competence and motivation and is a required attribute for PSE for symptom
management.
Competence. Knowledge and skills, including managing medical equipment and
communication with providers, are required to be competent in symptom management (Ryan &
Sawin, 2009). Competence also includes the physical ability to perform behaviors that could
include exercising for fatigue or changing a dressing. The capability of performing actions
required to manage symptoms is influenced by motivation, confidence, cognitive and affective
processes and is needed for PSE for symptom management.
Awareness. PSE is being aware of the ability to be effective, which includes competence,
physical ability and controlling actions (Zulkosky, 2009). Symptom awareness is being cognizant
of a sensation, something not known, and interpreted considering the experience (Rhodes &
Watson, 1987). Symptoms are subjective and only known when persons report their presence
(Rhodes & Watson, 1987). Awareness of symptoms includes recognizing new needs in relation to
symptoms and the needed response of actions for management (Fu et al., 2004). PSE for
symptom management occurs when persons are aware of changes in their bodies, or the
perception of abnormal feelings or symptoms, and then have the confidence, motivation, and
competence to respond to the situation.
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Constructed cases
Model case. A model case is an example of a how the concept is used that incorporates
all of the defining attributes of a concept (Walker & Avant, 2011). A woman diagnosed with
leukemia who has undergone several rounds of chemotherapy described her self-efficacy for
symptom management prior to her diagnosis, and in subsequent hospitalization and treatment.
Her statement: “Since I was diagnosed with cancer, I’m more aware of my body and I pay
attention to changes in how I feel” demonstrates cognitive processes and symptom awareness.
She demonstrates motivation by stating “I’ll do whatever it takes to stay out of the hospital” and
“…the more I do for myself, the more I get to stay out of the hospital, and that means everything
to me”. She continued: “I know the symptoms of infections, I was able to monitor that pretty
well. I check my central line for signs of infection. I had mucositis so I couldn’t eat or talk, I had
to force myself to get pills down. I performed oral care four times a day and ate soft foods. Then
my blood counts went up and my mucositis went away and it was better.” These statements show
that she is competent and has the cognitive ability to manage a complex regimen. Recognizing
changes, being aware of her body and feelings of fear demonstrate affective processes,
multidimensionality, dynamics, and awareness. She states, “I’m confident in myself because I
know I can’t always rely on others”, further demonstrating that she perceives herself to have selfefficacy for symptom management.
Contrary case. A contrary case is an example of not having self-efficacy for symptom
management where none of the attributes are present (Walker & Avant, 2011). Patients may not
recognize that self-efficacy is not present, and do not take steps to manage symptoms. This is the
situation in this contrary case of a middle-aged woman with lymphoma who did not report
developing tingling pain on the right side of her chest and upper arm. During a physical exam, the
health care provider identified a rash with small blisters. When asked about the rash, the woman
said, “I felt it but didn’t think it mattered, they told me to expect these things.” She said “why
didn’t I tell my husband? I don’t know” and “I don’t follow through, I had a problem and I didn’t
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tell anybody”. These statements reflect lack of cognitive processes and motivation and lack of
awareness that action could be taken to manage these symptoms.
Antecedents
Antecedents must be in place prior to occurrence of a concept (Walker & Avant, 2011).
The antecedents of PSE for symptom management in cancer patients are presence of symptoms,
performance accomplishments, verbal persuasion and perception of threat or fear.
Presence of symptoms. Symptoms bring awareness of new needs followed by the
response of patients to the needs (Fu et al., 2004). Symptoms indicate changes in biopsychosocial
functioning, sensations or cognition and provide clinical information (Dodd et al., 2001). In
addition to symptom presence, persons also perceive the severity and amount of distress or
discomfort (Rhodes & Watson, 1987). How symptoms are perceived can affect the intensity of
the symptom experience (Brant, 2016).
Dynamic. Cancer is a dynamic disease, with remissions and recurrences possible
(Gapstur, 2007). Symptom management includes evaluating symptoms, determining the meaning
and the required behavior, and is affected by types of symptoms, timing (during or after active
treatment), environment (home or hospital) and expected outcomes. Each time a symptom occurs,
the cycle of evaluation, determining meaning and behavior is repeated (Fu et al., 2004). Changes
in management strategies may also occur. PSE is a product of environment, cognition, affective
processes, and physical components that are all dynamic (Hoffman, 2013). Presence of stress,
anxiety and depression affects PSE (Bandura, 1997).
Multidimensional. Symptom presence and the behaviors required for management are
multidimensional, having physical, cognitive, emotional, social, and situational components
(Armstrong, 2003; Brant, 2016; Lenz, Pugh, Milligan, Gift, & Suppe, 1997). Symptom
management includes perception and cognition, as well as responses to experience, the illness,
expected outcomes and environment (Fu et al., 2004). How persons perceive their symptoms and
the resulting PSE for symptom management is multidimensional (Armstrong, 2003).
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Performance accomplishment. Successful performance of behavior builds PSE
(Bandura, 1997). Encouragement of performance accomplishments includes allowing persons to
practice a behavior or use return demonstration which, when successful, promotes increased PSE
(Zulkosky, 2009). Conversely, failure to perform a behavior may decrease PSE. Distractions,
complexity of the task, emotional state, and expertise of the individual modeling the behavior all
affect the ability to perform behavior (Richard & Shea, 2011). People take pride in their
accomplishments when they believe their success is due to their own efforts and will expend
more effort on tasks or behaviors when they believe they are proficient (Zulkosky, 2009).
Verbal persuasion. Verbal persuasion is when someone convinces another that they
have the capability for a behavior such as symptom management (Zulkosky, 2009). When
persons hear encouragement, they are more likely to use greater effort (Bandura, 1997). Persons
can be convinced that they can be successful at task performance. Verbal persuasion can be from
health care providers, family and friends, or other patients such as in support groups.
Presence of threat or fear. Symptoms may be perceived as a threat to individual’s
health (Hoffman, 2013). Evaluation of symptoms involves the intensity, location, frequency and
affective impact and the threat posed by the symptom (Dodd et al., 2001). The presence and
experience of symptoms may bring a perception of fear and threat, determining whether it is
dangerous or potentially disabling, which is the catalyst for initiating management activities (Fu
et al., 2004). Interpreting symptoms as recurrence or worsening of the cancer may cause
avoidance behavior that will negatively influence PSE (Hoffman, 2013).
Consequences
Consequences are a result of the occurrence of a concept (Walker & Avant, 2011). The
consequences of PSE for symptom management in cancer patients include symptom relief, health
status, cost of care, quality of life and performance of the management behavior.
Symptom relief. Low PSE for symptom management may result in poorly managed
symptom clusters that result in increased distress, increased depression, and anxiety, decreased
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functional status and impact relationships and daily life (Kim, McGuire, Tulman, & Barsevick,
2005). Other costs of unmanaged symptoms include increased health care utilization and
interference with treatment schedules which can lead to cancer worsening (Kim et al., 2005).
Increased PSE for symptom management Effective symptom management leads to symptom
relief, decreased distress, and decreased symptom occurrence (Fu et al., 2004).
Health status. Health status includes indicators such as relief or worsening of symptoms,
functional status, symptom distress level and survival (Fu et al., 2004). Symptom occurrence is an
indicator of health status and patient functioning.
Cost of care. Symptom management impacts cost of health care through use of
resources, treatment related services, and hospitalizations (Brant, 2016; Gapstur, 2007). Cost
benefit ratio is important in evaluating various symptom management interventions (Brant, Beck,
& Miaskowski, 2010). Cost is another component of multidimensionality of symptom
management.
Quality of life. Symptom presence and effects have a negative effect on QOL including
role performance, functional status, physical performance, cognitive functioning, delay of
treatment, and disease status (Brant, 2016; Gapstur, 2007). Self-efficacy has been linked to
symptom distress, psychological health, and QOL (Bergkvist et al., 2015; Hochhausen et al.,
2007; Kohno et al., 2010; Lee, Robin Cohen, Edgar, Laizner, & Gagnon, 2006; Liang et al., 2016;
Liao et al., 2014; Wu et al., 2012). Effective symptom management leads to decreased number or
presence of symptoms and directly impacts QOL (Fu et al., 2004). PSE for symptom management
can lead to prevention of symptoms and increased QOL.
Behavior Performance. Symptom management in persons with cancer is complex.
Persons with low PSE may experience more stress and depression and have lower motivation
(Zulkosky, 2009). Performance of symptom management behavior requires problem solving,
physical function mastery, and role function (Buffart et al., 2014; Fu et al., 2004). Those with
cognitive deficits are challenged in managing complex treatment regimens. Increased number and
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severity of symptoms can be related to lower cognitive functioning or ineffectual management
behaviors (Fu et al., 2004). PSE for symptom management allows persons to perform the
behaviors needed for symptom management.
Empirical referents
Empirical referents are how one recognizes or determines the existence of concepts and
are used to develop instruments to measure concepts in research (Walker & Avant, 2011). Selfefficacy can be measured by asking a person if they have confidence in taking an action (Lorig &
Holman, 2003). Measurement instruments that have been used in research include the general
PSE scale (Jerusalem, Schwarzer, & Schwarzer, 1992), the Arthritis Self-Efficacy Scale (Lorig,
Chastain, Ung, Shoor, & Holman, 1989), the Breast Cancer Self-Efficacy Scale (Champion et al.,
2013) and the Patient-Reported Outcomes Measurement Information System (PROMIS) selfefficacy scales for managing chronic conditions (American Institute for Research, 2016).
Instruments related to PSE for symptom management in cancer patients include the PSE for
Fatigue Self-Management tool (Hoffman et al., 2011) and the Symptom-Management SelfEfficacy Scale-Breast Cancer (Liang, Wu, Kuo, & Lu, 2015).
Discussion
Many publications exist in nursing literature regarding the broad concept of self-efficacy.
Limited literature is published that combines PSE with symptom management in cancer patients.
The concept characteristics described here take prior work by Bandura in the Self-Efficacy
Theory (1997) and others and applies it to the situation of PSE for symptom management in
cancer patients. This concept analysis also further expands upon the concepts that are in the
Theory of Symptom Self-Management by Hoffman (2013). PSE for symptom management is
easily influenced, positively or negatively, because of the dynamic state of cancer diagnosis and
subsequent treatment. Presence of symptom clusters has the potential to increase the level of
symptom distress and complexity of care and is an important when considering how to enhance
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PSE for symptom management. Individuals with high PSE for symptom management may have
decreased symptom occurrence, symptom distress and higher QOL (Porter et al., 2008).
Implications for Nursing
Recognizing deficits in PSE for symptom management is critical for providing overall
care for persons with cancer. Gaps may exist between PSE and ability for symptom management.
Persons may have high PSE but may not have the emotional, cognitive, or physical capability to
perform needed behaviors. A person with self-efficacy for symptom management may perceive
symptoms as less distressing. Nurses are positioned to help patients learn new behaviors for
managing symptoms. Interventions to increase self-efficacy, which include partnering, goal
setting, education, social support, and internet tools, can aid in making decisions for symptom
management (Foster et al., 2016; Goldberg, Hinchey, Feder, & Schulman-Green, 2016; Lee et al.,
2006; Myall et al., 2015; Ruland et al., 2013; Schulman-Green & Jeon, 2015; Weber et al., 2007;
Zhang et al., 2014; Zhu, Ebert, & Wai-Chi Chan, 2017). Symptom burden may be a barrier for
implementation of PSE interventions. PSE for symptom management is an ever-changing concept
within a dynamic cancer environment that requires changes of strategies over time.
Conclusion
PSE for symptom management can be learned (Hoffman, 2013). Using individualized
plans of care based on the attributes, antecedents and consequences provided here, nurses can
partner with cancer patients to reduce symptom burden, facilitate effective symptom
management, increase health status and QOL. Conceptual definition and clarity allows for future
research initiatives and interventions. This concept should be used in further research regarding
symptom management in cancer patients, especially in persons with complex symptomatology
such as those with multiple co-morbid conditions, advanced disease or receiving intense
treatments. Future research is warranted to find ways to increase self-efficacy for symptom
management in cancer care and thus improve patient outcomes.
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Figure 1: Perceived Self-efficacy for Symptom Management
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Table 1: Concept Analysis of Perceived Self-efficacy or Self-efficacy
Author
Robb, 2012

Concept
Self-efficacy in nursing
education

Attributes
Confidence
Perceived capability
Perseverance

Townsend &
Scanlan, 2011

Self-efficacy related to
student nurses in the
clinical setting

Confidence
Capability
Persistence
Strength

Zulkosky, 2009

Self-efficacy

Cognitive and
affective processes
Locus of control

Antecedents
Event occurrence
Reaction to event
Interpretation of behaviors
needed
Judgment of capability to
perform required behavior
Mastery experiences
Vicarious experiences
Social persuasion
Physiological and affective
state
Social experiences
Performance
accomplishment
Verbal persuasion
Physiologic cues

Consequences
Person decides to perform
behavior
Person decides not to
perform behavior
Person performs behavior
after verbal persuasion
Approach vs. avoidance
Quality of performance
Persistence

Low levels of self-efficacy:
Avoid complex
responsibilities
Lower motivation
Giving up
Higher stress and
depression
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Table 2: Concept Analysis of Symptoms in cancer patients
Author
Armstrong, 2003

Concept
Symptom
experience

Attributes
Symptom occurrence and distress
Situational and existential meaning

Fu, et al., 2004

Symptom
management

Gapstur, 2007

Symptom
burden

Subjective
Experiential
Intentional
Multidimensional
Dynamic process
Positive and negative outcomes
Dynamic
Multidimensional
Quantifiable
Subjective
Physiologic

Kim et al., 2005

Symptom
clusters

Relationships of symptoms
Relationships of clusters
Concurrence
Underlying dimensions
Stability
Common etiology

Antecedents
Demographic
characteristics
Disease
characteristics
Individual
characteristics
Not given

Consequences
Adjustment to illness
QOL
Mood
Functional status
Disease progression
Survival
Symptom status
Quality of life
Performance

Multiple
symptoms
related to
worsening
disease status

Decreased survival
Poor prognosis
Delay or termination of
treatment
Increased hospitalizations,
medical costs
Decreased functional status
Lowered self-reported QOL
Poorer physical health status
Interference with activities
of daily living
Emotional distress
Increased financial burden

Presence of 2 or
more symptoms
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Self-efficacy for Management of Symptoms and Symptom Distress in
Adult Cancer Patients: An Integrative Review
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Abstract
Aims: The purpose of this integrative review is to identify and assess the evidence regarding self-efficacy
and management of symptoms and symptom distress in adults with cancer.
Background: Self-efficacy for symptom management plays a key role in outcomes for cancer patients
such as quality of life (QOL), functional status, symptom distress and health-care utilization.
Design: Integrative literature review.
Data sources: A database search was performed for publications from 2006-2017. Articles that examined
the relationship between self-efficacy and symptom management or self-efficacy and symptom distress in
adult cancer patients were selected for inclusion.
Review methods: All publications were critically appraised for methodological quality. Data were
extracted and analyzed according to the review aims and key findings.
Results: Twenty publications met the inclusion criteria. The studies reviewed found high self-efficacy to
be associated with low symptom occurrence and symptom distress and higher general health and QOL.
High self-efficacy predicted physical and emotional well-being. Low self-efficacy was associated with
higher symptom severity, poorer outcomes, and overall functioning. Presence of self-efficacy can be
assessed using developed instruments and self-efficacy enhancing interventions are feasible and effective.
Conclusion: This integrative review provided information on the existing literature regarding self-efficacy
for symptom management in the cancer population. Presence of a theoretical model and validated
instruments to measure self-efficacy for symptom management set a groundwork for needed future
research into patient-centered interventions to enhance self-efficacy for symptom management.
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Impact Statement
Self-efficacy for symptom management plays a key role in outcomes for cancer patients such as
quality of life (QOL), functional status, symptom distress and health-care utilization. This integrative
review examined 20 publications to assess current evidence regarding self-efficacy for management of
symptoms and symptom distress in adults with cancer. Results showed that high self-efficacy is
associated with lower symptom occurrence and distress and better general health and QOL. Nurses are
well positioned to implement interventions to enhance self-efficacy for symptom management. Future
research needs to develop and test patient-centered interventions to enhance self-efficacy for symptom
management.

Summary Statement
This integrative review provides information on existing literature regarding self-efficacy for
symptom management in the cancer population. High self-efficacy leads to better symptom management
behaviors and lower symptom distress, better functioning, and overall quality of life. Groundwork is
present in the literature to support further research into patient-centered interventions to enhance selfefficacy for symptom management.
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Introduction
Changes in screening, early detection methods, and advances in treatments have resulted in a
decrease in overall death rates and an increase in the number of persons living with cancer in the United
States (Jemal et al., 2017; Miller et al., 2016). Living with cancer increases the complexity of care as
persons often have other chronic illnesses in addition, such as heart disease, diabetes, or chronic lung
disease (Hoffman, 2013). Acute and long-term symptoms related to a cancer diagnosis are both physical
and psychological and result from not only the disease process but also from the treatments. Symptom
management is an important part of the plan of care for cancer patients as uncontrolled symptoms impact
quality of life (QOL), functional status, perception of health, cost of health care, and survival (Brant,
2016).
Self-efficacy is a key component of self-management of symptoms and is vital for
implementation of the behaviors needed for self-management of symptoms. People are motivated to act
only when they believe they can influence results (Bandura, 2001). Studies have shown that self-efficacy
positively influences self-management behavior and is linked to higher QOL and improvements in health
status including lower physical and psychological symptoms (Lorig & Holman, 2003; Phillips &
McAuley, 2013; Porter, Keefe, Garst, McBride, & Baucom, 2008; Torbit, Albiani, Crangle, Latini, &
Hart, 2015).
Symptom management is a key component of nursing and cancer care (Armstrong, 2014). Cancer
patients’ symptoms occur frequently, in clusters (two or more symptoms co-occurring) and lead to
symptom burden and/or distress (Fu, McDaniel, & Rhodes, 2007; Gapstur, 2007; Kim & Abraham,
2008). Self-management of symptoms optimizes outcomes and influences QOL and survival in patients
with cancer (McCorkle et al., 2011). The outcomes of unmanaged symptoms include higher symptom
distress and disease progression along with lowered self-reported QOL, functional status and survival
(Gapstur, 2007).
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Self-efficacy and symptom management are key concepts that affect outcomes for cancer patients
in all stages of treatment. Understanding self-efficacy, symptom distress and the role that symptom
management strategies have in controlling symptoms is imperative for maintaining or potentially
improving functional status and QOL for cancer patients. The purpose of this integrative review is to
examine current experimental and non-experimental research as well as theoretical and empirical
literature regarding self-efficacy and the management of symptoms and symptom distress in adults with
cancer.
Background
According to Bandura’s Social Cognitive Theory (1986), self-efficacy is a person’s belief in their
ability to implement behaviors to achieve a desired outcome, such as symptom management, and includes
not only using the skills required to perform a behavior, but also knowing how and when to use them
under diverse circumstances. Self-efficacy can be learned, and therefore self-efficacy for symptom
management can be learned (Hoffman, 2013). As self-efficacy increases, persons become empowered to
change behaviors that are vital for self-management. Unless people believe they can have an influence on
results, they are not motivated to act (Bandura, 2001). Self-efficacy has been associated with future health
status and must be considered when teaching symptom management behaviors (Lorig & Holman, 2003).
Symptoms are a subjective experience that reflects a change from the normal state and are
important cues that bring problems to the attention of the caregiver (Dodd et al., 2001). The experience of
distress from the presence of a symptom or cluster of symptoms is the catalyst for a person to report their
presence and seek help (Fu et al., 2007). Symptom management in cancer is “a dynamic and
multidimensional process in which patients intentionally and purposefully act on and interact with the
perception (or previous perception) of the symptom(s) to initiate activities or direct others to perform
activities to relieve or decrease distress from and prevent the occurrence of a symptom” (Fu, LeMone, &
McDaniel, 2004, p. 68). Symptom management begins with awareness, presence of discomfort or
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suffering, identification, and assessment of symptoms from the persons’ perspective (Fu et al., 2004).
Symptom management includes the presence of one or more symptoms, the symptom experience
(intensity, distress, quality, temporality, appraisal), the effectiveness of interventions and the
measurement of related outcomes (Brant, 2016). Symptoms often occur in clusters and require different
methods of management, which increases the burden on the patient and their caregiver. For example, pain
may exacerbate depression, anxiety, or fatigue, adding to the complexity of care.
Symptom distress is a global term that represents the amount of suffering experienced by patients
in relation to the perception of the symptoms that are present (Holland et al., 2013). Symptom distress is
measured by self-report and is caused by presence of symptoms along with concerns about illness or
prognosis, disease treatment and side effects, psychosocial or spiritual issues or financial concerns
(Holland et al., 2013). The most distressing symptoms may not be the most severe, and the inability of
patients to manage distressing symptoms is often the reason for seeking care (Badger, Segrin, & Meek,
2011). Symptom distress is a key area of focus for clinical interventions as it has been shown to
negatively affect outcomes, including higher anxiety and depression, functional status and QOL
(Anderson et al., 2007; Bevans et al., 2014).
Self-efficacy positively influences self-management behavior and is linked to higher QOL and
improvements in health status including lower physical and psychological symptoms (Lorig & Holman,
2003; Porter et al., 2008). Self-management of symptoms impacts cost of health through treatment-related
services, hospitalizations and use of the health care system (Gapstur, 2007; Ryan & Sawin, 2009). Selfmanagement of symptoms has been shown to optimize outcomes and influence QOL and potentially
survival in patients with cancer (Hoffman, 2013; McCorkle et al., 2011).
Self-efficacy for symptom management is a predictor of patient outcomes for chronic disease
populations (Kelleher, Somers, Locklear, Crosswell, & Abernethy, 2016). The Oncology Nursing Society
Research Agenda identified symptom management and self-management as priorities (Knobf et al.,
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2015). The National Institute for Nursing Research also identified symptom science and self-management
as priority research areas (National Institute for Nursing Research, 2016).
The aim of this integrative review was to identify, assess and synthesize data from current
experimental and non-experimental research as well as theoretical and empirical literature regarding selfefficacy for management of symptoms and symptom distress in the adult cancer population. The concepts
of interest are self-efficacy for symptom management in the population of adult patients with cancer and
subpopulation pre-or post-hematopoietic stem cell transplant (HSCT). The sampling frame includes
research studies and theoretical publications.
Methods
This is an integrative review of publications in the nursing literature focusing on the concepts of
self-efficacy for symptom management and symptom distress. The methodological approach used was the
five-stage approach from Whittemore and Knafl (2005) of problem identification, literature search, data
evaluation, data analysis and presentation. This method was chosen as it allows for inclusion of
experimental and non-experimental research studies as well as theoretical publications in the analysis
A search was performed using the databases CINAHL, Cochrane Library, MEDLINE,
Biomedical Reference Collection, PsychINFO, NIH Reporter and Google Scholar. A keyword search
using MeSH terms included, but was not limited to self-efficacy AND symptom management, selfefficacy, AND symptom distress, and HSCT and cancer. The initial search was limited to HSCT patients
only. Due to the limited number of publications found, the search was widened to include the population
of cancer patients. The search was limited to January 2006-April 2017 to capture the most recent
literature as cancer treatment and symptom management strategies change frequently. Additional articles
were identified manually by searching references of retrieved articles. The first author selected journal
articles based on the inclusion and exclusion criteria. Decisions were reviewed by the second author.
Inclusion criterion were publication dates between 2006-2017, English language, discussion of outcomes
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or concepts of self-efficacy for symptom management and symptom distress, and population of adult
patients with cancer or undergoing HSCT. Exclusion criteria included pediatric population, caregivers of
HSCT or cancer patients, and unpublished manuscripts (dissertations).
Search Outcomes
Figure 1 presents a flowchart of the identification of relevant articles. The initial search yielded
338 articles. After examining titles and abstracts in relation to the inclusion criteria and excluding
duplicates, 35 were selected for full text review for relevance. Nine additional articles were retrieved from
a manual search of references from full text reviews. Of these 44 articles, 24 were excluded based on
exclusion criteria, primarily outcomes or concepts not directly related to the self-efficacy for management
of symptoms or symptom distress. Twenty articles were selected for inclusion in this review (Table 1).
Eighteen research studies were selected including five intervention studies and 13 descriptive studies. One
integrative review and one theory paper were included in the review as the data presented were directly
relevant to self-efficacy and symptoms in this population.
Quality Appraisal
The selected publications were published in peer reviewed journals. The research articles were
evaluated for quality of methodology using a quality appraisal tool developed by blending components of
tools in published reviews from Lines, Hutton, and Grant (2016) and Guo, Whittemore and He (2011)
(Table 2). Criteria for quality appraisal included the study design, methodology, sample, instruments,
analysis methods and key findings. Studies that were randomized controlled trials were also evaluated
using criteria from the Critical Skills Appraisal Programme (CASP, 2017) (Table 3). The integrative
review article selected for inclusion was evaluated using review criteria adapted from CASP criteria
(Table 4). The theoretical publication was evaluated based criteria from Walker and Avant (2011) (Table
5). No papers were rejected based on methodological quality.
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Data Abstraction and Synthesis
Publications were synthesized based on factors that influenced self-efficacy for management of
symptoms and symptom distress in persons with cancer. To facilitate the synthesis, data were extracted
into an evidence table. This supported comparison of populations, methodologies and analyses relating to
similarities in outcomes (Table 1).
Results
The 20 articles reviewed were from 18 studies from the United States, Sweden, Scotland, United
Kingdom, Taiwan, Norway, Greece, and China. The participants were patients with breast, lung, prostate,
colorectal, gastrointestinal, or hematologic cancer or were undergoing treatment with chemotherapy or
HSCT or had advanced cancer. Sample sizes ranged from 74 to 325 for the 17 quantitative studies and
eight for the mixed methods study. The mean age across all studies was 57.7 years.
The relationship between self-efficacy and symptoms is established in cancer patient populations.
Higher self-efficacy has been associated with higher symptom management and lower symptoms
(Bergkvist et al., 2015; Oakley, Johnson, & Ream, 2010; Porter et al., 2008). Higher self-efficacy for
coping with symptoms was associated with greater well-being (Shelby et al., 2014). Paterson, Robertson,
and Nabi (2015) reported a decrease in self-efficacy when symptoms significantly increased for men with
prostate cancer. Patients low in self-efficacy reported higher levels of symptoms and symptom distress
including pain, anxiety, fatigue, and functional well-being (Bergkvist et al., 2015; Kelleher et al., 2016;
Mystakidou et al., 2010; Papadopoulou et al., 2017; Porter et al., 2008). Reduced symptoms, better
performance status, and overall general health also contribute to self-efficacy (Bergkvist et al., 2015;
Hoffman, 2013; Mystakidou et al., 2010).
For HSCT patients, higher self-efficacy after transplant results in increased health related QOL,
lower depression and better general health (Bergkvist et al., 2015; Hochhausen et al., 2007). Lower selfefficacy after transplant resulted in poor general health and higher symptom occurrence (Bergkvist et al.,
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2015). Cognitive function is a factor to consider for self-efficacy for symptom management in these
patients as high doses of chemotherapy required for HSCT regimens may lead to impaired cognition. Wu
et al. (2012) suggests that interventions to increase self-efficacy will reduce the negative impact of
subjective cognitive impairment. There is an association between self-efficacy, general health, the
occurrence of symptoms, and ability to manage symptoms (Bergkvist et al., 2015; Hochhausen et al.,
2007; Wu et al., 2012).
Self-efficacy impacts QOL though lower symptom occurrence and distress in cancer patients
(Hochhausen et al., 2007; Liang et al., 2016; Mystakidou et al., 2010). Liang (2016) found that selfefficacy for symptom management mediated the association between symptom distress and QOL in breast
cancer patients. Lower symptom distress led to better QOL through higher self-efficacy. Other
publications support the relationship between self-efficacy and QOL in lung, prostate, breast, and
colorectal cancer patients (Hoffman, 2013; Mosher et al., 2016; Papadopoulou et al., 2017; Porter et al.,
2008; Shelby et al., 2014; Zhang et al., 2014).
Instruments to measure self-efficacy should measure a person’s beliefs in their ability to perform
the task within the situation of the study, in this case, symptom management (Bandura, 1997). There are
validated and reliable instruments available to measure self-efficacy for various behaviors in specific
cancer populations (Hoffman et al., 2011; Liang, Wu, Kuo, & Lu, 2015). Liang et al. (2015) developed
and tested an instrument that measures self-efficacy in women with breast cancer and included items
regarding communication, the severity of symptoms, managing emotional and interpersonal disturbances
and acquiring resources while undergoing chemotherapy. Hoffman et al. (2011) developed and validated
an instrument to measure self-efficacy for fatigue self-management for patients undergoing
chemotherapy. These instruments are self-report measures and have the potential for use to assess selfefficacy in other contexts in cancer populations.
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This review included four intervention studies designed to enhance self-efficacy. While the
interventions varied in methodology, all resulted in improved self-efficacy (or trends) or lower symptom
severity or distress. Zhang et al. (2014) developed a nurse led intervention that included self-efficacy
education, management of symptoms, relaxation techniques, and health coaching. Hoffman et al. (2017)
used an exercise and balance intervention to impact fatigue severity and found that as behavior
performance increased, self-efficacy for the behavior improved when compared to a control group.
Ruland et al. (2013) discussed an internet intervention that provided symptom self-management
information and support and allowed for communication and a diary. Oakley et al. (2010) used a diary
intervention for symptom communication and medication scheduling. These interventions show promise
for increasing self-efficacy and symptom management behaviors and decreasing symptom distress. An
integrative review conducted by Zhu, Ebert, and Wai-Chi Chan (2017) found that internet based programs
moderated by healthcare providers have positive effects on self-efficacy and symptom distress in women
with breast cancer during treatment.
Discussion
The publications in this review demonstrate a link between self-efficacy, management of
symptoms and symptom distress and QOL. The presence of self-efficacy not only predicted higher
physical and emotional well-being but also was associated with lower symptom occurrence and symptom
distress. This, in turn, leads to better overall health and improved quality of life. Barriers such as impaired
cognitive function must be considered when evaluating self-efficacy. While the study by Wu et al. (2012)
described in this review discussed impaired cognitive function in those patients having HSCT, it should
be noted that other patients who receive chemotherapy treatment are also at risk for impaired cognitive
function (Ahles, Root, & Ryan, 2012; Cohen, Shonka, Armstrong, & Wefel, 2014). Other barriers to
developing self-efficacy for symptom management include patients having the belief that nothing can be
done to alleviate symptoms or difficulty interpreting the cause of the symptom and whether to report them
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to their health care provider. However, a barrier to effective symptom management is low or lack of selfefficacy.
Assessment of patient’s self-efficacy for symptom management provides a guide for directing
care interventions. Instruments are available that are short and convenient for patients to complete either
by paper or electronic means (Kelleher et al., 2016). As demonstrated by the few intervention studies
selected for this review, more research is needed into effective self-efficacy enhancing interventions that
can be tailored for patients or caregivers to use for problem-solving and managing symptoms. The Theory
of Symptom Self-Management can be used as a framework to support the development of self-efficacy
enhancing interventions (Hoffman, 2013).
Nurses are well positioned to assess patient’s self-efficacy and to impact the development of
patient-centered interventions to assist patients to manage their symptoms related to cancer and treatment.
Nurse led interventions have been shown to be feasible and effective for increasing self-efficacy and
decreasing symptom severity and distress. These interventions include not only education regarding
symptom management, but mechanisms for patients to communicate and discuss the presence of
symptoms. Patients with low self-efficacy may not feel empowered to communicate the presence of
symptoms, especially if the symptoms are related to managing emotions such as anxiety or depression, or
seem mild in nature. Providing mechanisms for communication of symptom presence followed by
education of how to manage those symptoms has the potential to impact distress and QOL. The few
intervention studies available to enhance self-efficacy for symptom management in oncology patients is
an indication that more research is needed on this topic. Focusing research on a specific phase of
treatment such as during chemotherapy, during intensive treatment such as HSCT, or post-treatment,
allows for the development of patient-centered interventions.
A limitation of the research on this topic is that except for the studies from China and Taiwan, the
patient population was mostly Caucasian. Lack of diversity is a common finding in studies regarding
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HSCT patients. The lack of diversity affects the ability to generalize findings and potential development
of interventions to other populations. Another limitation of the review findings is the variability of stages
of illness of the participants. Studies presented in this review had participants that included those newly
diagnosed, undergoing treatment and 1 year or more post-treatment. The studies for HSCT patients were
conducted at one-year or later post-HSCT when the potential for symptom burden is less than during the
acute phase of transplant. There are no publications that assess self-efficacy during the acute phase of
HSCT when symptoms are the most intense. The cross-sectional methodology of some of the selected
studies is also a limitation, as self-efficacy has the potential to change depending on phase of treatment
and severity of symptoms. A limitation of this review is that the studies selected for inclusion were
English language. There may be relevant studies published in other languages that were omitted in this
review. Strengths of this review are the use of a framework to guide the selection of studies and analysis
and the use of quality appraisal tools specific to the publication type. The inclusion of articles from a
variety of countries is also a strength of the review.
Conclusion
Recognizing deficits and intervening to enhance self-efficacy is critical for providing overall care
for those cancer patients with presence of symptoms or symptom distress. Targeted interventions to
enhance self-efficacy while promoting symptom management behaviors would assist patients in
navigating the treatment experience, decrease symptom occurrence, and improve functional status and
QOL. Research into interventions that would achieve these goals is necessary to improve QOL for adult
patients with cancer.
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Figure 1: Flow Diagram of Article Selection
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Table 1: Selected Publications
Reference
Setting and sample
(Bergkvist et
Sweden;
al., 2015)
Patients who had
received an allogeneic
HSCT for a
hematological disease
(median 5 years posttransplant)
(Hochhausen et United States;
al., 2007)
Leukemia patients who
received an allogeneic
HSCT (1-year posttransplant)
(Hoffman et al.,
2009)

(Hoffman et al.,
2011)

United States;
Patients with breast,
lung, colon, and other
sites of cancer,
undergoing
chemotherapy and
experiencing symptoms
of pain or fatigue
United States;
Patients with breast,
lung, colon, and other
sites of cancer,
undergoing
chemotherapy and
experiencing symptoms
of pain or fatigue

Purpose / aim
Compare general health,
symptom occurrence, and selfefficacy long-term survivors of
HSCT who had received either
home care or hospital care
during the early phase after
HSCT.
Examine effects of pre-HSCT
social support, self-efficacy, and
optimism in predicting postHSCT health related QOL

Test a theoretical model with
the hypothesis that physical
functional status is predicted
through patient characteristics,
cancer-related fatigue, other
symptoms, and perceived SE for
fatigue self-management
Describe the development and
testing of the Perceived Selfefficacy for Fatigue
Management (PSEFSM)
instrument

Methods
Quantitative;
Descriptive
Cross-sectional;
Survey

Quantitative;
Descriptive
Longitudinal;
Telephone survey at
baseline and posttransplant
Quantitative;
Secondary data
analysis;
Cross-sectional
Survey

Quantitative;
Instrument
development

Findings
No differences in general
health, symptom occurrence or
self-efficacy between hospital
and home care groups
High SE was associated with
better general health and lower
symptom occurrence
Social support, self-efficacy
and optimism significantly
predicted physical and
emotional well-being post
HSCT
Results validated the model;
Perceived SE had a positive
effect on functional status and
served as a mediator between
cancer related fatigue and
physical functional status

PSEFSM demonstrated
reliability and validity and can
be used to measure perceived
SE for fatigue selfmanagement in the chronic
illness population
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Reference
(Hoffman,
2013)

Setting and sample
United States;
Cancer patients

Purpose / aim
Describe how nurses can apply
a tested middle-range theory in
in clinical practice to
to increase patient’s perceived
SE
Investigate effects of an exercise
intervention to promote
perceived self-efficacy for
fatigue self-management

(Hoffman et al.,
2017)

United States;
Post-surgical patients
with non-small cell lung
cancer

(Kelleher et al.,
2016)

United States;
Patients with breast and
gastrointestinal cancer

Examine how patient reported
outcomes of SE for pain,
function and other symptoms
were associated with pain,
symptom severity and distress,
and physical and psychosocial
functioning

(Liang et al.,
2015)

Taiwan;
Women with breast
cancer

Develop and evaluate the

reliability and validity of the
Symptom -Management SelfEfficacy Scale--Breast
Cancer (SMSES-BC) in
chemotherapy

Methods
Theoretical model;
Exemplars

Quantitative;
RCT;
Surveys in person and
telephone pre-surgery,
post-surgery, and
weeks 1, 3 and 6;
weekly diary;
functional outcomes
pre-surgery, postsurgery, and weeks 3
and 6
Quantitative;
Descriptive;
Cross-sectional;
surveys

Quantitative;
Instrument
development

Findings
Nurses can use perceived SE
enhancing symptom selfmanagement interventions to
improve functional status and
QOL of cancer patients
Intervention was feasible;
intervention group improved
in perceived SE for fatigue
self-management; fatigability
was reduced and mental and
physical health components of
functional performance in
intervention group improved
when compared to control
group
SE scores for pain and other
symptoms correlated
positively with pain, symptom
severity and distress, and
physical and psychosocial
functioning
Patients with lower levels of
SE had poorer outcomes and
functioning overall
SMSES-BC has acceptable
reliability and validity for
measuring symptommanagement self-efficacy
related to chemotherapy
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Reference
(Liang et al.,
2016)

Setting and sample
Taiwan;
Outpatients with breast
cancer

Purpose / aim
Examine association between
symptom distress and QOL;
Propose symptom management
SE as a mediator between
symptom distress and QOL

Methods
Quantitative;
Descriptive;
Cross-sectional survey

(Mosher et al.,
2016)

United States;
Lung cancer patients
and their family
caregivers

Examine efficacy of a telephone
based symptom management
intervention

Quantitative;
RCT;
Survey at baseline, 2
and 6 weeks

(Mystakidou et
al., 2010)

Greece;
Advanced cancer
patients in a palliative
care unit

Assess the relationship and
influence of demographic and
clinical characteristics on SE
beliefs

Quantitative;
Descriptive
Cross-sectional
survey

(Oakley et al.,
2010)

United Kingdom;
patients treated with
oral chemotherapy and
health professionals that
cared for them

Gain insight into the patient
experience; develop
understanding of complexities
in receiving oral chemotherapy;
investigate the use of a diary
and the impact on selfmedication, symptom
management adherence and
self-efficacy

Mixed method;
Literature review,
ethnographic study,
feasibility study
Participant
observation;
Informal
conversations;
Field notes and
reflective diary;

Findings
Symptom management selfefficacy mediated the
association between symptom
distress and global QOL,
functional QOL and symptom
QOL; Lower symptom distress
was indirectly associated with
better QOL through higher SE
No significant differences
between groups in symptoms,
SE for symptom management
or perceived social constraints
from the caregiver
SE significantly correlated
with levels of anxiety, physical
condition, and demographics;
SE is influenced by
components of anxiety, age,
physical performance, and
gender
Themes of relinquishing
control and moderating
factors;
Trends showed an association
between effective symptom
management and increased SE
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Reference

Setting and sample

Purpose / aim

(Papadopoulou
et al., 2017)

England, Scotland,
Northern Ireland;
Patients with breast or
colorectal cancer
scheduled to receive
adjuvant chemotherapy

Explore changes over time in
SE and predictive ability of
changes in state anxiety and
health related QOL during
chemotherapy

(Paterson et al.,
2015)

United Kingdom;
Men newly diagnosed
with prostate cancer

To test social support theoretical
model and detail selfmanagement behaviors

(Porter et al.,
2008)

United States;
Patients with early stage
lung cancer and their
caregivers

Examine SE for managing pain,
symptoms, and function;
Examine associations between
SE and patient and caregiver
adjustment

(Ruland et al.,
2013)

Norway;

Examine effects of an internetbased interactive health
communication application on

Methods
Formal interviews;
Intervention
development
Quantitative;
Descriptive;
Longitudinal;
Surveys prior to
starting chemotherapy
and at the start of 6
subsequent
chemotherapy cycles
Quantitative:
Longitudinal;
Surveys at baseline
and 6 months;
Subsample completed
diaries
Quantitative;
Descriptive;
Cross-sectional
Telephone survey

Quantitative;
RCT;

Findings

No significant time effects for
overall SE;
SE significantly associated
with decreased anxiety at all
time points;
Significant relationship
between SE and health-related
QOL at all time points
Self-management SE
significantly reduced at 6
months;
Significant decline in QOL at
6 months post-diagnosis
Patients low in SE reported
significantly higher levels of
pain, fatigue, lung cancer
symptoms, depression,
anxiety, and significantly
worse physical and functional
well-being;
When patients and caregivers
both had low SE, the patient
had higher anxiety and poorer
QOL
Significant effect on symptom
distress;
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Reference

Setting and sample
Patients with breast or
prostate cancer and
undergoing treatment
United States;
Women with breast
cancer taking adjuvant
endocrine therapy

Purpose / aim
symptom distress, depression,
SE, health related QOL and
social support
Examine the relationships
between physical symptoms, SE
for coping with symptoms, and
functional, emotional, and social
well-being

Methods
Surveys at 3, 6, 9 12
months

Findings
no significant differences in
other outcomes

Quantitative;
Descriptive;
Cross-sectional;
Survey

(Wu et al.,
2012)

United States;
HSCT survivors with at
least moderate distress
𝑥̅ = 1 year 8 months
post-HSCT

Examine whether SE for
symptom management mediates
relations between subjective
cognitive functioning and
psychological adjustment and
health related QOL

Quantitative;
Descriptive;
Cross-sectional
Survey and telephone
interview

(Zhang et al.,
2014)

China;
Colorectal cancer
patients diagnosed
within the last 6 months

To test effects of a nurse led SE
enhancing intervention

Quantitative;
RCT;
Survey at 3 and 6
months

Higher SE for coping with
symptoms was associated with
greater functional, emotional,
and social well-being after
controlling for physical
symptoms;
SE for coping with symptoms
moderated the relationship
between physical symptoms
and functional and emotional
well- being
Subjective cognitive
impairment reduces
confidence in ability to
manage common post-HSCT
symptoms;
Better subjective cognitive
functioning associated with
greater self-efficacy for
symptom management, which
in turn was associated with
less depressed mood. reduced
anxiety and better QOL
Intervention group had
significant improvement in SE
and a reduction in symptom
severity, symptom
interference, anxiety, and
depression.

(Shelby et al.,
2014)

compared to routine care
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Reference
(Zhu et al.,
2017)

Setting and sample
Reviewed publications
in Chinese and English;
Women with breast
cancer undergoing
treatment

Purpose / aim
Synthesize studies regarding
effectiveness of internet based
interactive programs on
symptom distress, social
support, SE, QOL and
psychological well-being

Methods
Integrative review

Findings
Internet based interactive
programs moderated by health
care professionals have
positive effects on SE,
symptom distress, and
psychological well-being, but
inconclusive effects on social
support and QOL

HSCT=Hematopoietic Stem Cell Transplant; RCT = Randomized Control Trial; SE=Self-efficacy; QOL= quality of life
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Table 2: Quality Appraisal for Selected Quantitative Studies
Confounding
factors or
limitations
identified

Data
analys
is
suffici
ently
rigoro
us

Clear
statement
of
findings

Can
the
results
be
applied
to
another
context

Y

Y

Y

Y

Y

Y

Y

y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

N

Unknown

N

Y

Y

Y

Y

Y

Y

Y

Y

N

Unknown

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

N

Unknown

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

N

Y

Y

Y

Y

Y

Mystakidou
et al., 2010

Y

Y

Y

N

Unknown

Unknow
n

Y

Y

Y

Y

Y

Y

Oakley, 2010

Y

Mixed
methods

Y

N

Unknown

N/A

N

Y

Y

Y

Y

Y

Author / date

Bergkvist et
al., 2015
Hochhausen
et al., 2007
Hoffman et
al., 2009
Hoffman et
al., 2011
Hoffman et
al, 2017
Kelleher,
Somers,
Locklear,
Crosswell, &
Abernethy,
2016
Liang, Wu,
Kuo, & Lu,
2015
Liang et al.,
2016
Mosher et al.,
2016

Did the
study
address
a
clearly
focused
issue

Methodology
appropriate

Sample
size

Power
analysis
included

Recruitment
strategy
appropriate

Response
rate %

Y

Y

Y

N

Y

Y

Y

Y

N

Y

Y

Y

Y

Y

Y

Instrument
reliability
/ validity
reported

Outcome
accurately
measured
to
minimize
bias

Y

Y

Y

Y

N

Y

Y

N

Y

Y

Y

Y

Y
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Author / date

Papadopoulou
et al., 2017
Paterson,
Robertson, &
Nabi, 2015
Porter, Keefe,
Garst,
McBride, &
Baucom,
2008
Ruland et al.,
2013
Shelby et al.,
2014
Wu et al.,
2012
Zhang et al.,
2014

Confounding
factors or
limitations
identified

Data
analys
is
suffici
ently
rigoro
us

Clear
statement
of
findings

Can
the
results
be
applied
to
another
context

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

N/A

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

N

Unknown

N

Y

Y

Y

Y

Y

Y

Y

N

Y

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Did the
study
address
a
clearly
focused
issue

Methodology
appropriate

Sample
size

Power
analysis
included

Recruitment
strategy
appropriate

Response
rate %

Y

Y

Y

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y
Y
Y

Instrument
reliability
/ validity
reported

Outcome
accurately
measured
to
minimize
bias

N

Y

Y

Y

N

Y

Y

Y

Y

Y

Y
Y
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Table 3: Quality Appraisal for Randomized Controlled Trials

Reference

Hoffman
et al., 2017
Mosher et
al., 2016
Ruland et
al., 2013
Zhang et
al., 2014

Aside from
the
intervention,
were the
groups
treated
equally?

How large
was the
treatment
effect?
(outcomes
measured,
primary
outcome
clearly
specified,
results for
each
outcome?)

How
precise was
the estimate
of the
treatment
effect?
(confidence
limits)

Can the
results
be
applied?

Were all
clinically
important
outcome
considered?

Are the
benefits
worth the
harms and
costs?

Was the
assignment
of patients to
treatments
randomized?

Were all
the patients
who
entered the
trial
properly
accounted
for at its
conclusion?

Were
subjects
blind to
treatment?

Were the
groups
similar at
the start
of the
trial?
(other
factors
that
might
affect
outcome)

Y

Y

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

N

Y

Y

Y

N

Y

Y

Y

Y

Y

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

N

Y

Y

Y

N

Y

Y

Y
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Table 4: Quality Appraisal for Review Article

Reference

Did the
publication
address a
clearly focused
question?

Did the authors
review the right
type of
publications?

Were all
important,
relevant studies
discussed and
included?

Did the authors
do enough to
ensure the quality
of the
publication?

If the results of
the review
were
combined, was
it reasonable to
do so?

Were all
important
outcomes
considered?

Clear
statement of
findings?

Can the results
be applied to
another
context?

Zhu, Ebert,
& Wai-Chi
Chan, 2017

Y

Y

Y

Y

Y

Y

Y

Y
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Table 5: Quality Appraisal for Theoretical Article

Reference

Did origins of
the theory
refer to its
initial
development?

Does the meaning
relate to the
theory’s concepts
and how they
relate to each
other?

Does the
theory
have
logical
adequacy?

Usefulness: Is the theory
practical and helpful to
the discipline and
provide a sense of
understanding or
predictable outcome?

Can
generalizations
be made from
the theory?

Parsimony: Can the theory
be stated simply while still
being complete in the
explanation of the
phenomenon in question?

Is the theory
testable?

Hoffman,
2013

Y

Y

Y

Y

Y

Y

Y
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CHAPTER IV: Manuscript 3

Self-efficacy for Symptom Management in the Acute Phase
of Hematopoietic Stem Cell Transplant
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Abstract
Context: Hematopoietic stem cell transplant (HSCT) is an intensive treatment associated
with distressing treatment and disease-related symptoms that affect patient outcomes such
as functional status and quality of life. Self-efficacy for symptom management (SESM) is
a person’s belief in their ability to perform behaviors to prevent and relieve symptoms.
Presence of SESM can impact symptom distress and functional status.
Objectives: This study describes the changes over time and relationships among SESM,
symptom distress, and physical functional status in adults during the acute phase of
HSCT.
Methods: Patients (n = 40) completed measures of symptom distress, SESM, and
physical function at time points prior to, and at days seven, 15 and 30 post-transplant.
Clinical outcomes were length of stay and number of readmissions.
Results: Symptom distress, physical function, and SESM changed significantly over time.
There was a significant negative relationship between symptom distress and physical
function and between symptom distress and SESM at all time points. The lowest levels of
SESM and physical function were at day seven when symptom distress was highest.
Symptom distress was a moderator for the relationship between physical function and
SESM at day 15.
Conclusion: This is the first study to examine SESM in the acute phase of HSCT. Higher
SESM was associated with fewer symptoms and increased physical function. Less
symptom distress is associated with higher physical function and confidence to manage
symptoms. These findings provide the basis for development of patient-centered
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interventions to enhance SESM when symptoms are at their highest immediately after
HSCT.
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Introduction
Hematopoietic stem cell transplant (HSCT) is an intensive treatment option for
some types of cancer. The HSCT process includes conditioning chemotherapy with or
without radiation treatments, followed by infusion of stem cells, either from the patient
themselves (autologous) or from a sibling or unrelated donor (allogeneic). Disease
diagnosis, stage, and donor availability determine transplant type. Regardless of the type
of transplant a person receives, treatment-related symptoms are severe and can have
significant effects on patient outcomes such as functional status and quality of life (QOL)
(Andersson, Ahlberg, Stockelberg, & Persson, 2011; Pidala, Anasetti, & Jim, 2009;
Wong et al., 2010). The presence of concurrent symptoms is greater during the first 30
days and along with other factors such as physical, psychosocial, or emotional issues
causes symptom distress (Anderson et al., 2007; Bevans, Mitchell, & Marden, 2008;
Cohen et al., 2012). Helping patients to manage their symptoms during the intense
treatment period immediately after HSCT may improve the symptom experience and
influence patient outcomes.
Self-efficacy is the belief of a person in their ability to perform behaviors
(Bandura, 1997). Self-efficacy for symptom management (SESM) is the ability to
implement behaviors to prevent, recognize, and relieve symptoms in cancer patients
(White et al., in press). SESM requires not only knowledge and skills, but also cognitive
processes, motivation, and confidence (Hoffman, 2013; White et al., in press). The
relationship between self-efficacy and symptom distress is not known, however, presence
of self-efficacy has been linked to better general health, lower symptom occurrence and
better physical and emotional well-being after HSCT (Bergkvist et al., 2015; Hochhausen
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et al., 2007; Wu et al., 2012). Self-efficacy, measured prior to HSCT, significantly
predicted physical and emotional well-being one year after HSCT (Hochhausen et al.,
2007). Self-efficacy was associated with decreased symptoms and was a significant
predictor of emotional and physical well-being and QOL for those who were one year or
more post-transplant (Bergkvist et al., 2015; Hochhausen et al., 2007; Wu et al., 2012).
Patients who undergo HSCT experience high symptom burden and symptom
distress (Bevans et al., 2008; Braamse et al., 2014). Symptoms that have been shown to
be most distressing are both physical and psychological in nature and include fatigue,
weakness, sleep disturbances, worry or anxiety, lack of appetite, bowel problems and
pain (Anderson et al., 2007; Bevans et al., 2008; Cohen et al., 2012). Highest symptom
intensity occurs between 10 and 14 days after conditioning chemotherapy is initiated and
usually return to baseline by day 30 post-transplant (Anderson et al., 2007; Campagnaro
et al., 2008). Symptoms usually present in clusters, and have an additive effect,
increasing the burden on patients and their caregivers (Cleeland, 2007). Consequences of
high symptom burden include decreased survival, depression, delay in treatment,
increased hospitalizations, and medical costs (Cleeland, 2007; Gapstur, 2007). HSCT
patients with high symptom distress are more likely to be non-adherent with medication
regimens, have sleep disturbances, anxiety, and depression, which can lead to increased
hospital length of stay (Bevans et al., 2011; Lee et al., 2005; Rischer, Scherwath, Zander,
Koch, & Schulz-Kindermann, 2009). Stress from the HSCT process, along with symptom
distress has been shown to impact blood count recovery and overall health in the acute
phase of transplant (Hobfoll et al., 2015). High symptom distress and inadequate
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symptom management has a negative effect on physical and mental health, functional
status, and ultimately, QOL (Bevans et al., 2014; Cleeland, 2007; Gapstur, 2007).
Both the Oncology Nursing Society and the National Institute for Nursing
Research have identified symptom management as a priority for research (Knobf et al.,
2015; National Institute of Nursing Research, 2016). These priority areas include studies
of factors that influence the management of symptoms and contribute to the design of
personalized interventions. This study of SESM in HSCT patients aligns with these
research priorities.
The relationship between SESM and symptom distress in HSCT patients is
unknown. The purpose of this study was to describe the changes over time and
relationships among SESM, symptom distress, and the outcomes of physical function,
readmission, and length of stay during the acute phase (30 days) post-HSCT. The specific
aims were:
1. Determine the changes over time in SESM, symptom distress, and physical
functional status.
2. Examine the relationships among SESM, symptom distress, and physical
function.
3. Determine if the relationships among SESM and length of stay, readmission rates,
and functional status varied depending on the level of symptom distress.
Methods
Design and Participants. This was a longitudinal, descriptive, pilot study. After
obtaining institutional review board approval (Appendix A and B), participants who were
undergoing either autologous or allogeneic HSCT were recruited consecutively from a
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single center in the Midwestern U.S. Inclusion criteria were that patients were at least 19
years old and met evaluation criteria for undergoing a stem cell transplant. Exclusion
criteria were that the patient did not speak English or could not sign their consent.
Hertzog (2008) suggests a sample size of 20 to 25 for single group pilot studies.
The initial enrollment goal was 30 participants to allow for attrition. When enrollment
exceeded expectations, IRB approval to increase enrollment was sought and obtained
(Appendix C and D). Forty-six patients were eligible for the study. Two were excluded
for exclusion criteria and four declined to participate. Reasons for not participating were
“not good at answering questions” and “not interested.” The final sample was 40
participants.
After signing consent, participants completed paper/pencil surveys at baseline,
which was after admission to the hospital and before beginning the conditioning
chemotherapy regimen. Post-transplant time points were at 7, 15 and 30 days after
transplant. A brief interview was conducted with the participant at baseline and day 30 to
obtain the patient’s perspective on SESM during the transplant process. These results are
reported elsewhere (White, Cohen, Berger, Kupzyk, & Bierman, under review).
Measures. Variables measured in this study included demographic and clinical
data, symptom distress, SESM, physical functional status, length of stay and readmission
rates.
Demographic and clinical data. Demographic and clinical data were collected
from patients during baseline data collection and from the medical records. Data
collected included gender, race, age, employment status, educational level, marital status,
the presence of a caregiver, type of disease, type of transplant, comorbidity score, length
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of stay for transplant admission, number of readmissions and length of stay for
readmission within 30 days after transplant. Comorbidity scores were calculated using the
Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI). The HCT-CI score
measures health status prior to transplant and considers both comorbidities and age as
prognostic factors (Sorror et al., 2014). The scores were divided into three risk groups;
low (0-2), medium (3-4) and high (>5) with a higher score indicating a higher mortality
risk (Sorror et al., 2005).
Symptom distress. Symptom distress was measured using the Symptom Distress
Scale (SDS) (McCorkle, 1987) (Appendix F). The tool is a cancer-specific, 13-item selfreport questionnaire that uses a one to five scale ranging from no distress to extensive
distress to measure the degree of distress from 11 different symptoms that are frequently
reported by cancer patients. The symptoms, in order of presentation on the tool, are
nausea, appetite, insomnia, pain, fatigue, bowel pattern, concentration, appearance,
breathing, outlook, and cough. The remaining two items in the tool assess the frequency
of nausea and pain (McCorkle, Cooley, & Shea, 1998). A total score of 25 or greater
indicates moderate distress while a score of 33 or greater is considered severe distress
(McCorkle et al., 1998). Reliability and validity have been demonstrated previously
(McCorkle et al., 1998; Stapleton, Holden, Epstein, & Wilkie, 2015). Cronbach’s alpha
was .823 at baseline and ranged from .694 - .864 in this study.
Self-efficacy for Symptom Management. SESM was measured using the Selfefficacy for Managing Symptoms (SEMS) (Appendix G) and Self-efficacy for Managing
Medications and Treatment (SEMMT) (Appendix H) instruments selected from the
Patient-Reported Outcomes Measurement Information System (PROMIS) Self-efficacy
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for Managing Chronic Conditions measures (American Institute for Research, 2016). The
PROMIS tools are a collection of tools developed with funding from the National
Institutes of Health that use item response theory to measure patient-reported outcomes
(Gruber-Baldini, Velozo, Romero, & Shulman, 2017; Jensen et al., 2015). These are
newly developed tools and have limited reporting in the literature. Initial calibrations
across chronic conditions show good internal consistency and cross-sectional validity
(Gruber-Baldini et al., 2017). Reliability estimates have not been reported for the full
item banks.
The SEMS instrument has 28 questions with responses on a scale from one (not at
all confident) to five (very confident). The instrument includes items that assess persons’
level of confidence to manage their symptoms in different settings including hospital and
home and to keep symptoms from interfering with activities of life such as work, sleep,
relationships, or recreational activities (Patient-Reported Outcomes Measurement
Information System, 2015). Cronbach’s alpha reliability for this study was .973 at
baseline and ranged from .965 - .987 for other time points. The SEMMT has 26 questions
with the same scale from one to five. The items assess the person’s confidence in
managing medication schedules, managing medications in challenging situations,
understanding the difference between medication side effects and symptoms, and ability
to follow a treatment plan (Patient-Reported Outcomes Measurement Information
System, 2015). Cronbach’s alpha reliability for this study was .967 at baseline and ranged
from .975 - .988 at other time points.
Physical Function. Physical function was measured using the PROMIS Physical
Function – Short Form 10a (Appendix I). This 10-question form measures self-reported
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capability within the domains of role and physical function. Questions are rated on a 5point scale from “without any difficulty” to “unable to do.” This instrument has been
used in research with persons who have cancer and was found to be valid and reliable
across age and race-ethnic groups (Jensen et al., 2015). Jensen et al. (2015) reported the
Cronbach’s alpha in cancer patients to be from .92 - .96. The same study also reported
high convergent validity and discriminant validity. Cronbach’s alpha reliability for this
study was .855 at baseline and ranged from .904 - .914 at other time points.
Length of stay and readmission(s). Length of stay, number of readmissions and
readmission length of stay were tracked via the medical record and by self-report of
participants. Length of stay data were not reported for patients that died prior to or after
30 days post-transplant.
Data analysis
Descriptive statistics were obtained for all variables (means, standard deviations,
frequency distributions and percentages). Normality tests were performed and met the
assumptions of the statistical tests used in the data analysis in all but one case. Normality
was examined with skew and kurtosis indicating non-normality in the SEMS instrument.
These data were log transformed for further analysis.
For the first research aim, repeated measures analysis of variance (RM-ANOVA)
and paired t-tests were used to examine how SESM, symptom distress and physical
function changed over time. Paired samples t-tests were calculated to assess changes in
each of the variables between adjacent time points. The second research aim used
correlations to examine the relationship between SESM, symptom distress, and physical
function. A general linear model was used to examine if baseline SESM predicted
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changes in symptom distress and physical function over time. For the final aim,
interaction effects between SESM and symptom distress predicting physical function
were examined. Interaction plots, with inputs of ±1 standard deviation to indicate low and
high values of distress and self-efficacy, were used to interpret significant moderation of
the effect of symptom distress on functional status, length of stay and readmission rates.
Results
The demographic and clinical data are presented in Table 1 and Figures 1 and 2.
Approximately half of the sample was female, mean age of 58.27 years (SD = 8.73) at
baseline, and the race/ethnic distribution was almost exclusively white. Mean length of
stay was 12.84 days (SD 8.33) for both transplant types. Autologous transplant
recipient’s average length of stay at 12 days, and allogeneic transplants had an average
length of stay of 16 days. One person died before 30 days after transplant. The majority
were employed full time with the remaining participants retired, on disability or
unemployed. At least 70% had greater than a high school education and were married,
with their spouse as their caregiver.
Autologous transplant was the most common transplant type, and the most
common primary disease was multiple myeloma. The highest number of participants had
a comorbidity score in the medium risk range. Over 70% of the participants were not
readmitted to the hospital after discharge. At baseline, the most frequently occurring
symptoms were fatigue, pain, and insomnia (Figure 1). At days seven and 15, the most
frequently occurring symptoms were lack of appetite, fatigue, and bowel changes. At day
30, fatigue, lack of appetite, pain, and changes in appearance were most frequent. Severe
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and moderate distress levels were highest at day 7 and day 15 respectively, while the
lowest distress levels were at baseline and day 30 (Figure 2).
The first specific aim was to determine the changes over time in symptom
distress, SESM and physical functional status. Descriptive statistic means are presented
in Table 2 and Figures 3 and 4. At day seven, the mean score for symptom distress
peaked, and the means for self-efficacy and physical function were the lowest. For
symptom distress, change over time was significant [F (1.99, 57.64) = 14.94, p < .001].
There was a significant linear trend (p = .001) and a significant quadratic effect (p < .001)
indicating the slope changed over time. Dependent samples t-tests indicated a significant
increase in symptom distress between baseline and day seven, and significant decreases
between day seven and 15, and day 15 and 30 (Figure 3; Table 3).
Results from both the SEMMT and SEMS instruments were used to measure
SESM. There was a significant change in SEMMT over time [F (2.6, 75.4) = 5.318, p =
.003]. There was not a significant linear trend, but the quadratic effect was significant (p
= .012) indicating the slope changed over time. Paired t-tests indicated a significant
decline between baseline and day seven, and an increase between day seven and day 15
(Figure 4; Table 3). There was a significant change in SEMS over time [F (2.8, 80.89) =
7.418, p < .001] with a significant linear trend (p = .023) and a significant quadratic
effect (p = .001). Paired t-tests indicated a significant decline between baseline and day
seven, and increased between day seven and day 15, and between day 15 and day 30
(Figure 4; Table 3).
There were significant changes in physical function over time [F (2.8, 76.3) =
4.86, p = .004]. There was not a significant linear trend, but the quadratic effect was
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significant (p = .009). Paired t-tests indicated a significant decline between baseline and
day seven. No differences were found between other adjacent time points (Figure 4;
Table 3).
The second specific aim was to examine the relationships between SESM,
symptom distress and physical function. Table 4 presents correlation data. Significant
negative relationships were found between symptom distress and physical function and
between SESM and symptom distress at all time points. A significant positive
relationship was found between SEMMT and SEMS at each time point. There was a
positive relationship between SESM and physical function at all time points
The final specific aim was to determine if the relationship between SESM, length
of stay, readmission rates, and functional status varied depending on the level of
symptom distress. No moderating effects of symptom distress were found at baseline, day
7 or day 30. An interaction was found at day 15 between symptom distress and SESM
predicting physical function (p < .01). The interaction was marginally significant at day
seven (p = .06). In participants with low symptom distress, higher SESM was associated
with higher physical function. In participants with high symptom distress, higher SESM
was associated with lower physical function (Figure 5). The moderating effect of
symptom distress on the relationship between SEMMT and physical function mirrors that
of SEMS shown in Figure 5.
Discussion
This longitudinal, descriptive study examined relationships and changes over time
in SESM, symptom distress and physical function for adult patients receiving HSCT.
This is the first known report on SESM and symptom distress during the first 30 days
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after HSCT. The findings will now be discussed in relation to clinical data and each
specific aim and implications for nursing practice provided. Symptoms that caused
distress found in this sample are similar to what has been reported in other studies with
lack of appetite, fatigue, insomnia, and bowel changes common at day 15 and lack of
appetite, fatigue, and insomnia common at day 30 (Anderson et al., 2007; Andersson et
al., 2011; Bevans et al., 2008; Cohen et al., 2012). These studies did not report most
common symptoms at day seven. Bevans et al. (2008) reported levels of distress in
allogeneic transplant patients with the majority at a low level at baseline and 43%
moderate to severe levels at 30 days post-transplant. Levels between baseline and 30 days
post-transplant are not reported.
The first aim determined that there were significant changes over time in
symptom distress which is similar to other studies where symptom distress peaked at day
seven and returned to baseline levels by day 30 (Anderson et al., 2007; Cohen et al.,
2012; Hobfoll et al., 2015). Physical function also changed over time, which is consistent
with studies that show HSCT patients with higher symptom distress have lower physical
and mental health status (Anderson et al., 2007; Andersson et al., 2011; Bevans et al.,
2014).
SESM was measured using two instruments: the SEMS and SEMMT. Using each
tool contributed to a complete picture of SESM that included not only managing
symptoms with medications and a treatment plan (SEMMT), but also judgment regarding
symptom management, recognizing and managing new symptoms, and performing daily
activities or living a normal life, despite having symptoms (SEMS). SESM was lowest
when symptom distress was the highest, a time when management of symptoms is vital
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for outcomes. Changes over time in SESM have not previously been studied during the
acute phase of HSCT.
The second aim found significant relationships between SESM, symptom distress
and physical function during the acute phase of HSCT with higher SESM associated with
fewer symptoms and increased physical function. These findings are consistent with
results from other studies on HSCT patients, in which high self-efficacy was associated
with better general health and lower symptom occurrence and self-efficacy predicted
greater physical well-being (Bergkvist et al., 2015; Hochhausen et al., 2007). However,
the timing of these studies was between one and five years post-transplant. Wu et al.
(2012) reported in patients who were greater than one-year post-transplant, better
subjective cognitive functioning was associated with greater self-efficacy for symptom
management and led to less depressed mood, reduced anxiety, and higher QOL. Other
studies examined self-efficacy and symptoms and found those with lower levels selfefficacy reported higher symptom severity and distress, levels of pain, fatigue and worse
physical condition and performance (Kelleher, Somers, Locklear, Crosswell, &
Abernethy, 2016; Mystakidou et al., 2010; Porter, Keefe, Garst, McBride, & Baucom,
2008). These studies were in patients with cancer, not receiving HSCT and not during
acute treatment or hospitalization. The results of this study are significant in that they
confirm that SESM impacts symptom distress during the acute phase of transplant.
For the final aim, there was an interaction present between the moderator variable
of symptom distress, SESM and physical function at day 15. In participants with low
symptom distress, high SESM was associated with higher physical function. Having less
symptom distress has an impact on overall feelings of health and physical function and
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may increase confidence to manage symptoms. This interaction was only present at day
15. This may be due to symptom distress being at the highest level at day 7. When
patients feel their worst, as they were when their symptom distress was highest at day 7,
they may be unable to participate in symptom management activities. By day 15,
patient’s symptom distress is starting to lessen, and physical function and self-efficacy
are improving resulting in the moderation effects seen here. This conclusion is verified by
the patient’s perspective as patients described feeling too poorly to participate in their
care (White et al., under review). For example, when talking about his symptoms, one
patient stated, “I was sicker than a dog…there was no way I could have pulled myself
through or anything I could have done to make myself feel better.” Another patient
stated, “it didn’t matter what I did, I just felt horrible” and “for a long time in this process
I was not self-sufficient, and that’s tough.” As patients improve (day 15), the interaction
between symptom distress, SESM and physical function may be more apparent and then
return to baseline levels as symptoms lessen by day 30.
Evidence shows that interventions to reduce distress improve patients’ ability to
follow treatment regimens and improve outcomes of care (Holland & Alici, 2010).
Patients are being discharged from the acute care setting earlier and effective symptom
management is essential. Patients are expected to manage their symptoms and treatment
plans, but not all are able to do so. Having a plan of care that includes assessment of
SESM before HSCT will allow for patient-centered interventions to enhance SESM and
reduce symptom distress. Using the results from the assessment, multidisciplinary
interventions that are patient-specific can be developed. These could include focusing on
areas that impact SESM such as symptom awareness, feelings of anxiety, stress, or
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depression, setting goals and acting to meet them, in addition to knowledge of how to
manage treatment regimens and communication with care providers (White et al., in
press). The interventions would be targeted toward the patient’s need, whether it be
coaching, finding resources, or education for the caregiver. Ideally, implantation of these
interventions would occur when symptom distress is low, as high physical and
psychological symptom distress is a barrier to SESM (Wu et al., 2012).
Limitations
This study was a single-center study with a small sample size. Most of the
participants received autologous transplants. Allogeneic HSCT patients tend to have
more severe symptoms and a longer recovery time (Wong et al., 2010). Another
limitation is the lack of ethnic diversity, which is common in clinical care and HSCT
studies (Baker et al., 2009; Schriber et al., 2017). This makes the generalization of study
results difficult. White, non-Hispanic, and married persons tend to score self-efficacy at
higher levels (Gruber-Baldini et al., 2017).
Strengths
To the author’s knowledge, this is the first study that has used the PROMIS selfefficacy tools to measure SESM in the HSCT population. The combination of the SEMS
and SEMMT instruments for measuring SESM provided a more comprehensive view of
the concept. The participation rate was high with 87% of patients approached consenting
to the study. The questionnaire completion rate was 144 out of 160 data points (90%),
with most of the missing data due to participants being too ill to complete the surveys.
Symptom and SESM data from these patients would have been valuable as their
symptom experience was likely more severe.
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This is the first study found to examine SESM in HSCT patients and has
established the relationship between SESM, symptom distress and functional status in the
acute phase of HSCT and provides a foundation for future intervention research.
Enhancing SESM during all phases of transplant, but especially when symptoms are at
their most distressing, has the potential to improve symptom management and ultimately
patient outcomes. For HSCT patients with severe symptoms and complex treatment
regimens, nurses can assess and implement patient-centered interventions to enhance
SESM. Facilitation of self-efficacy will enable patients to manage their symptoms
effectively and lead to improved outcomes including functional status, QOL, and
decreased utilization of heath care resources.
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Table 1: Demographic and Clinical data (N=40)

Demographics (Baseline)
N
%
Women
18
45
Men
22
55
Race
White
39
97.5
Non-white
1
2.5
Employment
Full time
27
67.5
Disability
4
10
Retired
8
20
Unemployed
1
2.5
Education
Upper secondary (10-12)
10
25
Post-secondary (Vocational)
15
37.5
Associate’s Degree
2
5
Bachelor’s Degree
10
25
Post graduate Degree
3
7.5
Marital Status
Married
28
70
Single
6
15
Divorced
5
12.5
Widowed
1
2.5
Caregiver
Spouse
28
70
Family member
6
15
Friend
4
10
None
2
5
Primary Disease Acute Myelocytic Leukemia
9
22.5
Acute Promyelocytic Leukemia
1
2.5
Lymphoma
9
22.5
Myelodysplastic Syndrome
1
2.5
Multiple Myeloma
20
50
Transplant Type Autologous
29
72.5
Allogeneic
Related Allogeneic
7
17.5
Unrelated Allogeneic
4
10
Comorbidity
0-2
9
22.5
Score
3-4
19
47.5
>5
12
30
Readmissions*
0
29
72.5
1
6
15
2
1
2.5
* 3 patients were not discharged at 30 days post-HSCT; 1 patient was deceased.
Gender
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Table 2: Descriptive Statistics Means (SD) at all time points

Instrument
SDS
Physical Function
SEMMT

Baseline
11.85 (6.83)
42.06 (7.84)
45.81 (8.63)

Day 7
17.55 (8.20)
36.61 (7.44)
42.90 (8.66)

Day 15
13.64 (7.85)
38.61 (8.93)
45.69 (8.60)

Day 30
10.19 (6.17)
40.03 (8.56)
47.57
(10.46)
SEMS
47.29 (6.73)
44.48 (5.21)
46.58 (6.28) 48.75 (7.94)
Abbreviations: SDS = Symptom Distress Scale; SEMMT = Symptom Management for
Managing Medications and Treatments; SEMS = Self-efficacy for Managing Symptoms
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Table 3: Dependent Samples t-tests (p-values) at all time points

Instrument

Dependent Samples t-tests (p-values)
Baseline – Day 7 Day 7-15
Day 15-30

Baseline-Day
30
SDS
<.001*
.003*
<.001*
.083
Physical Function
<.001*
.187
.426
.107
SEMMT
.044*
.031*
.157
.430
SEMS
.008*
.027*
.024*
.406
Abbreviations: SDS = Symptom Distress Scale; SEMMT = Symptom Management for
Managing Medications and Treatments; SEMS = Self-efficacy for Managing Symptoms
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Table 4: Correlation between symptom distress, physical function, and self-efficacy

Symptom Distress

Physical Function

Correlation to SEMS scale r(p)
Physical
Function
SEMMT
Baseline
-.530** (.001)
-.324* (.044)
Day 7
-.499** (.004)
-.320 (.065)
Day 15
-.677** (<.001) -.272 (.120)
Day 30
-.463** (.007)
-.439* (.011)
Baseline
.268 (.094)
Day 7
.265 (.150)

SEMS
-.605** (<.001)
-.469** (.005)
-.614** (<.001)
-.602** (<.001)
.367* (.020)
.376* (.037)

Day 15
.136 (.457)
.539** (.001)
Day 30
.331 (.060)
.526** (.002)
Baseline
.541** (<.001)
Day 7
.655** (<.001)
SEMMT
Day 15
.559** (.001)
Day 30
.757** (<.001)
** Correlation is significant at the .01 level (2-tailed).
* Correlation is significant at the .05 level (2-tailed).
SEMMT = Self-efficacy for Managing Medications and Treatments; SEMS= Selfefficacy for Managing Symptoms Scale
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Figure 1: Average Symptom Distress
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Figure 2: Levels of Symptom Distress
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Figure 3: Symptom Distress Changes over time
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Figure 4. Physical Function and Self-efficacy for Symptom Management Changes over time
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Figure 5: Moderating effects at Day 15 (SEMS)
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CHAPTER V: Manuscript 4

The Meaning of Self-efficacy for Symptom Management in the Acute Phase of Hematopoietic
Stem Cell Transplant
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Abstract
Background: Hematopoietic stem cell transplant (HSCT) is an intensive treatment that offers the
potential for longer life or cure for some types of cancer. HSCT is associated with decreased
quality of life (QOL), functional status and distressing symptoms. Self-efficacy for symptom
management (SESM) is a person’s belief in their ability to implement behaviors to manage these
symptoms. Presence of SESM can affect symptom distress, health care utilization and posttransplant outcomes.
Objective: The purpose of the study was to explore the meaning of SESM in adults during the
acute phase of HSCT.
Methods: Interviews were conducted prior to and at 30 days post-transplant. Descriptive thematic
analysis was performed on verbatim interview transcripts.
Results: Themes of confidence, being responsible, and caring for mind, body, spirit were
identified with subthemes of self-confidence, confidence in other, confidence and symptom level,
vigilance, self-advocacy, and normalcy. Participants reported having high SESM pre-transplant,
and having much less or no SESM when symptom distress was the most severe.
Conclusions: This is the first study to examine the patient’s perspective of self-efficacy in the
acute phase of HSCT. This contributes to existing literature on the concept of symptom
management and expands nursing knowledge of SESM in patients undergoing HSCT.
Implications for Practice: Nurses can assess SESM prior to transplant and implement
interventions to enhance SESM when symptoms are at their most distressing after HSCT. The
findings from this study can provide the basis for creating behavioral interventions to enhance
self-efficacy for symptom management in HSCT patients.
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Introduction
Hematopoietic stem cell transplant (HSCT), also known as a stem cell or bone marrow
transplant, is a treatment that offers the potential for an extended length of life and cure for some
types of cancer. HSCT is an intensive treatment that is associated with decreased health-related
quality of life (QOL) and functional status along with distressing symptoms (Larsen, Nordstrom,
Ljungman, & Gardulf, 2007) Patients can receive donor stem cells either from themselves
(autologous) or from a sibling or unrelated donor (allogeneic). The type of disease the person has
along with the stage and donor availability dictate the type of transplant. The HSCT process
consists of evaluation testing and donor selection, intensive chemotherapy and possibly radiation
treatments, the stem cell reinfusion (transplant), and is followed by a recovery period. The acute
phase of HSCT, which is the first 30 days after transplant, is when the greatest risk for
complications exists and when symptom distress is the most severe. Patients often are discharged
from the hospital setting within 30 days after transplant and expected to self-manage symptoms.
Self-efficacy for symptom management (SESM) is vital during this time as prevention,
recognition and symptom relief during this time can be a complex process.
Background
Self-efficacy is a key component of the management of symptoms. Self-efficacy is a
person’s belief in their ability to implement behaviors to achieve a desired outcome (Bandura,
1986). Self-efficacy includes not only the confidence, but also the knowledge and skills,
motivation, and competence to perform the behavior under diverse circumstances (Hoffman,
2013). Studies have shown that cancer patients and those receiving HSCT who have high selfefficacy experience lower levels of pain, fatigue, and psychological distress and better general
health and QOL (Bergkvist et al., 2015; Porter, Keefe, Garst, McBride, & Baucom, 2008). Cancer
patients with lower levels of self-efficacy have been shown to have higher levels of pain, fatigue,
depression, anxiety and poorer functioning and overall outcomes (Kelleher, Somers, Locklear,
Crosswell, & Abernethy, 2016; Porter et al., 2008).
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Symptom management is a process that is dynamic and multidimensional (Fu, LeMone,
& McDaniel, 2004; White et al., in press). Self-efficacy for symptom management (SESM) is the
ability to implement behaviors to prevent, recognize, and relieve symptoms in cancer patients
(White et al., in press). SESM can be changed or influenced, in a positive or negative way,
because of the dynamic state of the disease process, and the intensity of the transplant process.
SESM plays a key role in outcomes for HSCT patients as symptom management affects symptom
distress, QOL, and health care utilization.
Many publications describe self-efficacy in cancer patients, but limited literature has been
published on self-efficacy in HSCT patients (Bergkvist et al., 2015; Hochhausen et al., 2007; Wu
et al., 2012). This study fills a gap in the literature regarding the meaning of SESM for patients
undergoing HSCT. The purpose of this study was to explore the meaning of SESM in adults
during the acute phase of HSCT.
Methods
Patients in this study were part of a longitudinal descriptive study that examined the
relationship between SESM and symptom distress during the first 30 days after HSCT. After
obtaining approval from the Institutional Review Board (Appendix A and B), patients who were
receiving autologous or allogeneic transplant were recruited consecutively at a single center.
Eligibility requirements for inclusion in the study were those receiving a transplant who are at
least 19 years of age. Exclusion criteria included not speaking English and not being admitted to
the hospital for the transplant. Forty-six patients were eligible for participation in the study. Two
were excluded for exclusion criteria, and four declined to participate. Reasons for not
participating were “not good at answering questions” and “not interested.” The final sample was
40 participants. The portion of the study reported here used qualitative descriptive methodology
and analysis was guided by thematic analysis (Braun & Clarke, 2006; Sandelowski, 2000; Willis,
Sullivan-Bolyai, Knafl, & Cohen, 2016).
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After participants had signed consent forms, the principal investigator (PI) conducted
interviews using open-ended scripted questions to ensure a standardized approach (Table 1).
Interviews were conducted at baseline (prior to transplant) and 30 days after transplant. The
baseline interview was conducted in person, in the participant’s hospital room shortly after
admission, but before initiation of the transplant chemotherapy regimen. If a caregiver was
present, they were given the option to stay for the interview. All post-transplant interviews were
completed via telephone, except for two interviews that were completed in person. All interviews
were digitally recorded and professionally transcribed verbatim. The PI verified the accuracy of
the transcription. The PI performed analysis with close consultation and recommendations by the
second author and verification by the interdisciplinary team. The researchers used the descriptive
analysis process outlined by Braun and Clarke (2006) to identify codes and search for themes
within the data. Themes were developed using multiple readings, examining entire transcripts,
and underlining and labeling passages with theme labels. Themes were reviewed, defined, and
named, and compared across factors such as the type of transplant and time of interview (pre- and
post-transplant).
Results
Demographic and clinical data
A total of 70 interviews from 40 patients were analyzed. Missing interviews were due to
patient death before 30 days (1), too ill to participate (4) and declined the final interview (5).
Demographic and clinical data were obtained from the participants and the electronic medical
record. Study participants ranged in age from 29 to 72 years with a mean of 58.27 years (SD
8.73). Eighteen (45%) were women, 22 (55%) men, and 39 (97.5%) were white. While 27
(67.5%) were employed full-time, the remainder were retired (8, 20%), on disability (4, 10%) or
unemployed (1, 2.5%). Educational levels were high school (10, 25%), post-secondary/vocational
and associate’s degree (17, 42.5%), and baccalaureate or post-graduate degree (13, 32.5%). The
majority were married (28, 70%) and their spouse was their primary caregiver.
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Most participants received an autologous stem cell transplant (n = 29, 72.5%), and 11
received an allogeneic stem cell transplant (related = 7, unrelated = 4). Cancer diagnoses were
multiple myeloma (20, 50%), leukemia (10, 25%), lymphoma (9, 22.5%), and myelodysplastic
syndrome (1, 2.5%). Comorbidity scores were calculated using the Hematopoietic Cell Transplant
Comorbidity Index (HCT-CI), which is a measure of health status that indicates mortality risk
after HSCT (Fred Hutchinson Cancer Research Center, 2017; Sorror et al., 2014). The score
considers both comorbidities and age with a higher score indicating a higher mortality risk.
Twelve (30%) of the participants were considered high risk with a score of 5 or greater, 19
(47.5%) had a score of 3-4, and 9 (22.5%) were in the low-risk group. The average length of stay
in the hospital after HSCT was 12.84 days (SD 8.33). Most of the participants were not
readmitted to the hospital after discharge (29, 72.5%). Six patients (15%) were readmitted one
time, and one patient was readmitted twice.
Themes
The meaning of SESM was described as confidence both in one’s self and in others.
Confidence included levels pre- and post-transplant as symptom distress varied. Level of
confidence was the only aspect that differed from pre-to post-transplant. Responsibility included
vigilance and advocacy. Caring for mind, body and spirit was identified as a theme and includes
normalcy. Themes were consistent between autologous and allogeneic transplant. Table 2
outlines the themes, subthemes, and further description follows.
Theme: Confidence
Self-confidence. When asked what SESM meant to them, the participants responded in
ways that reflected their confidence and perspectives on managing symptoms. Several
participants described the meaning of SESM in relation to the amount of confidence they felt,
“I’m pretty confident in my ability to care for myself”, and “I’m confident in explaining my
symptoms maybe, to a nurse, if I have a problem and how I feel about it; if I’m anxious about it.”
Another participant felt less confident after transplant, explaining, “I’m not real confident on the
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symptom side. I can describe what happened. I just don’t know why it happened or what I need to
do to correct it.” The dynamic state of the disease and transplant process was also a factor in
confidence, as reflected in the statements of “It’s the uneasiness of what is happening, what the
hell is happening, you know, uncertainty. That is when I don’t say I lose my confidence; it’s
shaken” and “Anybody who says their confidence isn’t tested is not being honest with
themselves, I think.” A 48-year-old woman who was discharged and then developed an infection
in her bowel described her experience as:
My confidence at home was getting pretty drained. There wasn’t much
left. When my doctor said he wanted to admit me, I was like almost
relieved at that point because I knew that I wasn’t at that point taking care
of myself the way I needed to be taken care of.
Post-transplant participants described their sense of SESM in relation to the environment,
whether in the hospital or at home after discharge. While some participants felt that SESM was
no different in the hospital than at home, others felt that the hospital was too controlled. One
person described being “micromanaged” in the hospital setting. Another described it in this way:
You feel like you don’t really have control over your own health because
they don’t really allow you to in a sense…take this pill when you are
scheduled to…and this is hospital policy and we do it at this time and blah
blah, but when you get out, you are able to make your own schedule and
do it the way you want- still right, still 12 hours apart but maybe not at 7
a.m. and 7 p.m., but now it’s 9 a.m. and 9 p.m. because that’s better for
me.
Another participant, a 61-year-old female autologous recipient, spent 14 days in the hospital posttransplant. She discussed her sense of confidence in her SESM as being limited by the nursing
staff, stating:
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The nurses…some of them were so over-zealous that I felt like they took
away my sense of self-efficacy. They were just so eager to – ‘don’t do this
without buzzing. Don’t do this.’ I know that there’s safety issues,
understandable, and they didn’t want me to fall, because obviously I was
weak and everything, but sometimes I just felt this sense of hovering.
One’s environment and feelings of control have an impact on self-confidence, both preand post HSCT. Participants described feeling that they needed to take control of themselves, that
they do not have or had lost control, or that they wanted control. Specific statements included
“Before this happened, I was an extremely healthy 52-year-old. I’m not anymore, and now all of
the sudden you’re in a situation where you’re out of control. Cancer controls it, you don’t” and
“It’s very frustrating, when you lose control.”
Confidence in others. Another aspect of confidence is in relation to those who are caring
for the HSCT recipients, both professional providers and non-professionals, such as spouses or
family members. The need for, and presence of confidence in their health care team was
expressed as, “I have a good feeling about it, mainly because of the confidence in my doctor,”
and “I felt confident in my care team, that they were on top of it and listened to me and reacted
properly and promptly.” Others related their confidence in relation to their support systems
stating, “All my family and friends are here…you gotta [sic] have a support team” and “Part of
symptom management is also relying on the support of your family.” A 66-year-old man talked
about discussing symptoms with his wife. He described how he felt lightheaded one day and said
“and so I collaborated with my wife on that, but if I had to think of that myself, I’d have never got
there. So, it’s nice to have somebody like that here.”
Confidence and symptom level. When responding to the question about how much SESM
they had prior to HSCT, participants expressed either they had a high level or a lot (25), were
ambiguous in their response (10), or did not give a direct answer (5). Those with high SESM
stated “I have the utmost confidence” and “I have all the confidence in the world.” Others were
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not as certain in their response, stating, “I’m hoping I’m good” and “Now it’s getting kind of real,
so, I don’t know.” Participants provided examples of how they had managed symptoms prior to
transplant. These included examples of symptom recognition such as “I’ve come to a point now
going through chemo that I recognize something’s going to happen and then I say here we go.”
One 68-year-old female who worked as a housekeeper described that she had high SESM because
she could tolerate symptoms stating, “A little pain is not going to bother me. It doesn’t bother me.
I’ve been known to – I walked around with a broken arm in two places for six weeks. I just kept
working.”
Post-transplant level of confidence varied depending on the transplant experience and amount
of symptom distress. For some, the experience was not as difficult as expected with comments
such as “I thought I got along pretty good, better than I thought” and “I would say it went pretty
smooth, things went like I expected they would have.” However, more often, participants
described their level of confidence as low when their symptoms were the most distressing. These
participants described their experience as: “You know you should be able to do something about
it but you can’t”, “I didn’t have as much [SESM] as I thought I would due to the fact it affected
me so bad”, “I tell myself I’m going to feel good, and the only time that didn’t work was when…I
had an infection, there was no way I could have pulled myself through it”, “I would have liked to
have done more for myself, and I was just so weak.” A 59-year-old female explained:
You just don’t feel good and there’s not much you can do about it. Then,
toward this last week or so, you feel better because you’re starting to feel
better and then you can do things or set little goals for yourself… Again,
it’s like as you felt better, then you were more confident in what you could
do.
A 63-year-old female who stated she had a high level of SESM prior to transplant stated,
“Beginning before I got sick, I had a lot of confidence, but then once I got sick and got all these
infections, I was pretty much just at everybody else’s mercy. I had no self-confidence at all.”
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Other participants commented in similar ways saying, “I always have self-confidence that I can
manage my own symptoms and there was a point in time there where I didn’t feel that way” and
“When you don’t feel well, nothing’s well, and that’s kind of a broad statement, but it takes it all
in.”
When describing the meaning of SESM from the post-transplant perspective, participants
elaborated on their symptom experience. Symptom recognition and presence is key to SESM. The
symptoms mentioned varied widely in type and severity. Most commonly discussed, in order of
frequency, were fatigue, lack of appetite, diarrhea, having an infection and/or fever, changes in
taste and weakness (Table 3). In addition to relating specific symptoms, some participants
described general feelings of being unwell. A 59-year-old male who worked in a professional role
described his experience as:
You just sit there, and I was unable to read because I couldn’t concentrate
from the chemo or from whatever, and they said that was normal, so I
couldn’t read a book. I had no interest in watching TV, and I ended up just
sitting there for days, what felt like five, six days, and I suppose I would
doze off and on. They didn’t want me in bed. They wanted me sitting and
up and moving because they thought that would help my recovery, and I’m
sure it did, so I tried to stay out of bed, but I just didn’t have any interest in
doing anything. I just kind of sat there.
One participant described it as “Bam, and pardon my words, you feel like crap, you literally feel
like crap…it doesn’t matter what you do, it’s not going away.” Another verbalized it as:
It was fatigue and just an overall blah feeling. I had no pain. I really wasn’t
nauseous. I just have never felt so bad. I can’t explain it. In all the things
that I’ve had, I guess I always equate pain with how I feel, and this was not
painful, but at the same time, I’ve never felt so rotten in my life, and it just
went day after day after day.
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One participant described her experience with mucositis after allogeneic transplant as:
The worst thing was the mucositis, it was really bad. I didn’t eat, couldn’t
talk, couldn’t do anything besides get some pills down, and that was
because I had to force myself. I literally would cry when I took them.
Theme: Responsibility
While confidence is a key component of SESM, responsibility and follow through are
also important. Being responsible was identified as a theme as participants discussed how they
view responsibility for care, advocacy, and symptom awareness.
Participants described the meaning of SESM as being responsible, which included
understanding, communication, and follow through. Participants stated SESM is “to express what
I feel and know what my symptoms are” and “to be able to take care of the symptoms myself,
recognize them and maybe do treatment for them.” Two other participants noted: “I know I’m
ultimately responsible, that I can’t expect everybody else to just do it” and “owning my response
to the symptoms and the procedures and following through with what needs to be done.” Others
viewed SESM looking toward the future saying, “it means to manage what I can, because I do
what I need to do knowing that if I don’t, then it’s going to cause something down the road” and
“if we don’t manage the symptoms, we’re not going to get better. We’re going to get worse, and
if we get worse, we don’t have anybody to blame but ourselves.”
Post-transplant responses were reflective of the HSCT and the responsibility of managing
the treatment regimen. Participants gave examples of how they demonstrated SESM after HSCT,
both before and after discharge from the hospital. Managing medications was a common
response, with one participant stating, “I keep asking to get off some of the drugs, because I’m
taking more medication than I want to take.” Another talked about the complexity of the
medication regimen:
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I’ve actually got a spreadsheet for my med list, for my nausea meds and
this and that, so if I do go on them, I can keep track of what time of the
day I took which one and all this and that.
Vigilance. Participants talked about being aware of their bodies, changes, and symptom
recognition both pre-and post-transplant. A 50-year-old male participant described the meaning of
SESM to him as “I’m watching for any infection or anything, something that might be out of
line.” Post-transplant comments included “I’m tired, but I think it’s me learning to be more aware
of – and not only being more aware but also acting upon, knowing when I’m fatigued”, “I’ve
stayed on top of it in terms of knowing what my body is, I take my temperature and my blood
pressure a couple times a day, so I’m pretty comfortable knowing if something goes wrong” and
“I ask myself - do I recognize the symptom as being a symptom or is it severe enough to report?”
A young woman, age 29, explained, “I’m just aware; I recognize, I kept myself aware of what to
look for and I get scared because I guess I not only have to care for myself, but I have to care for
my kids too.”
Self-advocacy. Having self-efficacy for a behavior such as symptom management
includes being able to advocate for one’s own needs. The theme of self-advocacy was repeated
pre-and post-transplant by these participants as “It means to be sure to relate to them [health care
team] my symptoms and keep things clarified and that both parties involved understand each
other for the best outcome” and “I’m not afraid to ask questions to find out the answers and carry
through with it.”
Some participants were very explicit in their belief in their self-advocacy stating, “If I
need to speak up for any help that I need, I’m not afraid to do that. I will self-advocate” and “I am
my own advocate. How about that? I am my own advocate. Because you have to be able to stand
up for yourself.” When describing how he had developed SESM, a 69-year-old man stated, “Now
any time my body changes or something changes, I speak up right away. I used to just keep it in
and go through it, but now things are a little bit more complicated, so I speak up.”
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Theme: Caring for mind, body, and spirit
Several participants described psychological and spiritual aspects of the meaning of
SESM in addition to the physical. Descriptions included attitude, seeking to be normal again,
taking their mind off their symptoms, and a holistic approach, in addition to acceptance and
coping. They described how having a positive attitude affected how they managed symptoms as
“My ability to accept what I’ve got to deal with and the way that I approach it with my attitude”,
“To me, it’s about having a positive attitude, I can manage my symptoms by telling myself that
I’m going to be better”, and “I think you have to have the right attitude, which gives you the
confidence to look forward to your journey.” One participant talked about avoiding negative
thoughts: “I just don’t dwell on the negative. I do give myself time to grieve about issues, which I
think is very important, but try not to go past that five-minute pity party.” Two participants talked
about the difficulties of managing their mindset stating, “This is the hard part. The head. Keeping
my head straight. I know the physical part is taken care of” and “Because I’ve always been a
tough guy and just, you know, and I got real frustrated because I couldn’t take it.” A 58-year-old
male stated post-transplant that:
I went in there with a fighter’s attitude and I think that’s a good thing,
because a little while there a person would usually want to give up, but I
didn’t want to do that. I want to be around for my family. I mean, there
was a tough time there for a bit, but I think I tried to use my positive
mental attitude to fight through it and it made me a lot more spiritual than
I’d ever been before.
One participant described a holistic approach to SESM stating, “You know you can’t just do the
medical part. You have to do the mind, the spirit, the body. You have to do it all, and I’ll never
forget that.” Another participant stated post-transplant that “It changes you physically and it
changes you mentally, as well. Hopefully, it’s mostly for the best.”
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Participants described symptoms that affected mind and body. One person described his
change in appearance as “I look in the mirror, and I see no hair. That’s what I see. Hey look, a
reminder of what you have.” Other responses included “I get moody or angry for no reason...my
family notices this and it’s hard”, “The mental is tough, I just want it over” and “This grand finale
is the transplant…its awful scary to me.”
Normalcy. Seeking to be normal again is an aspect that includes psychosocial and
spiritual in addition to the physical condition. Participants described wanting to be home or to get
back to work or other activities that were important to them both pre-and post-transplant.
Participants discussed being physically normal again by saying “I wanted my body back” and
“There’s a normalcy you have to have, in order to get back to it, but you have to do certain things
[physical therapy].” Others talked about wanting to return to activities they could do pretransplant such as driving: “I’m the kind of person that just wants to keep going, and this stuff’s
kinda [sic] cramping my style,” and playing golf “I’m anxious to get going again because I golf a
lot and I haven’t golfed in about a month and a half or two months.” Another participant
expressed uncertainty as: “Hopefully, by the time my 100 day’s post-transplant comes around, I’ll
be living a semi-normal life like I want, but there’s no promises.”
Conclusions
While there are research studies published on self-efficacy in HSCT patients (Bergkvist
et al., 2015; Hochhausen et al., 2007; Wu et al., 2012), we were unable to find other qualitative
research describing what self-efficacy means to patients in the acute phase of HSCT. Believing
that SESM is present will influence the choices they make to manage symptoms, the effort they
put forth and how they persist when there are setbacks (Bandura, 1991). Most of the participants
felt that they had high SESM before HSCT. Several participants related that as symptom distress
increased, self-efficacy lessened. Other studies also have shown that self-efficacy is significantly
associated with symptom severity such as pain, anxiety, distress, and symptom severity in cancer
patients (Kelleher et al., 2016; Mystakidou et al., 2010; Papadopoulou et al., 2017). This is the
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time in the HSCT process when symptom management interventions are most important, and
nursing interventions are vital to enhance or reinforce self-efficacy. Nurses should be mindful of
and balance patients’ personality, their level of SESM, and need for control when providing for
patient safety. Understanding individual patients’ experience will help guide nurses to provide
more interventions when necessary and to explain the rationale for these changes.
Other publications have discussed patients seeking normalcy at 100 days or longer after
HSCT (Hacker, 2003; Lyons et al., 2010; Mosher et al., 2011). Mosher et al. (2011) reported
patients seeking normal at between one and three years after transplant as they resumed work and
social roles and Hacker (2003) discussed normalcy as a concept within QOL. Returning to normal
is a part of psychological well-being and a way to measure recovery (Lyons et al., 2010; Whedon
& Ferrell, 1994). Results from this study show that patients are seeking to return to normal as
early as before HSCT and within 30 days post-transplant.
In prior studies, physical symptoms, distress, and QOL have been determined to be key
factors in the experience both pre-and post-transplant (Mosher, Redd, Rini, Burkhalter, &
DuHamel, 2009; Pidala, Anasetti, & Jim, 2009; Smith, Hobson, & Haig, 2016). Symptoms
frequently reported after HSCT include fatigue, worry, appetite changes, feeling sick, insomnia
and bowel changes (Anderson et al., 2007; Bevans, Mitchell, & Marden, 2008; Campagnaro et
al., 2008; Stapleton, Holden, Epstein, & Wilkie, 2015). Psychological distress that includes
anxiety is also common in HSCT recipients (Baliousis, Rennoldson, & Snowden, 2015; Mosher
et al., 2009). These findings are supported here by participants comments about anxiety, worry
and being scared. Assessment pre-transplant to identify patients who may be more
psychologically vulnerable or have anxiety or depression is important as they are at risk for
poorer outcomes and longer length of hospital stay (Cooke, Gemmill, Kravits, & Grant, 2009).
The patients in this sample highlighted the importance of health care providers providing holistic
care. Variability in reactions to the HSCT process and symptom burden between patients has
been documented and is influenced by chemotherapy regimen, comorbidities, disease state, prior
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treatment toxicities and other factors (Bevans et al., 2008; Campagnaro et al., 2008; Dahan &
Auerbach, 2006). The themes and interview excerpts presented here confirm the findings from
these other studies, add the concept of self-efficacy to the discussion, and give voice to the patient
perspective.
Interventions have been developed to enhance self-efficacy in cancer patients (Hoffman
et al., 2017; Zhang et al., 2014; Zhu, Ebert, & Wai-Chi Chan, 2017). Hoffman et al. (2017)
developed an intervention to increase self-efficacy for the management of fatigue. Other
interventions include a telephone based symptom management intervention, use of a diary, an
internet-based health communication application, and a nurse intervention that included
education, relaxation techniques for symptom management and health-coaching sessions (Mosher
et al., 2016; Oakley, Johnson, & Ream, 2010; Ruland et al., 2013; Zhang et al., 2014). SESM
enhancing interventions specifically for transplant patients have not been developed but should be
holistic and developed mutually with the patient to ensure strategies that are individualized to
patient needs and personality traits.
Limitations of this study include that themes were not validated with participants after the
analysis was completed, however, an interdisciplinary team verified the themes. A second
limitation is missing data from patients who were too ill or in the intensive care unit to complete
the final interview at 30 days post-transplant. The perspective of these patients, if they later
recovered enough to participate in an interview, would have been valuable as their symptom
experience was likely more severe and longer lasting than the other participants. Another
limitation is that the sample is from one center, lacks ethnic and education diversity and so results
may be different in other locations.
Implications for Practice
Nurses can help patients enhance their SESM. The findings from this study provide the
basis for creating and implementing behavioral interventions to enhance SESM. Patients’
understanding of SESM as confidence in self and others in addition to the changes in the level of
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confidence related to symptom distress are important findings to use when developing
interventions. Assessing patient’s SESM before HSCT to determine their needs for symptom
management will aid in the development and implementation of education or problem-solving
strategies to enhance symptom management when it is needed. Being responsible for behaviors,
being vigilant of changes, and speaking up when symptoms arise also are important topics to
include in interventions. Recognizing when patients are at risk for increased symptom distress
and decreased self-efficacy is important for timing of interventions. Patients with low SESM are
at risk for higher symptom distress and poorer overall outcomes (Kelleher et al., 2016).6 Patients
with high SESM that results in more effective symptom management have the potential for
improved outcomes such as higher QOL and functional status and lower symptom distress
(Bergkvist et al., 2015; Hochhausen et al., 2007; Hoffman, 2013). These findings add the patient’s
perspective to existing literature on both self-efficacy in HSCT and self-efficacy specifically for
symptom management.
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Table 1. Scripted Interview Questions
Baseline
1. What does self-efficacy for symptom management mean to you?
2. How much self-efficacy do you feel you have for symptom management?
3. Can you give examples?
30 days Post-transplant
1. How much self-efficacy did you have for managing your symptoms during the last 30
days?
2. Can you give examples?
3. What might have helped you to develop self-efficacy for symptom management?
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Table 2. Themes and Subthemes
Confidence
Self-confidence
Confidence in others
Confidence and symptom level
Responsibility
Vigilance
Self-advocacy
Caring for mind, body, spirit
Normalcy
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Table 3. Post-transplant Signs and Symptoms (in order of frequency discussed)
Discussed by > 5 participants Discussed by 3-4 participants Discussed by 1-2 participants
Fatigue
Anxiety
Insomnia
Lack of appetite
Frustrated
Change in appearance
Diarrhea
Pain
Weight loss
Infection/fever
Nausea/vomiting
Mucositis
Changes in taste
Scared
Rash/swelling
Weakness
Feeling unwell
Difficulty concentrating
Trouble breathing
Depression
Worry
Dehydration
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CHAPTER VI: DISCUSSION
Summary
The concept analysis, literature review and research results presented in this dissertation
add to existing literature on self-efficacy for symptom management (SESM) in the adult
hematopoietic stem cell transplant (HSCT) patient population. This research study establishes the
need for assessment of SESM prior to the transplant process and for the development and
implementation of patient-centered interventions to enhance SESM. The results of this study
showed a significant relationship between symptom distress, SESM and physical function (health
status) as was described in the conceptual model in Chapter I.
Chapter II provided an analysis of the concept of perceived SESM in cancer patients
using the Walker and Avant (2011) method and included the definition, attributes, antecedents,
and consequences of perceived SESM. Perceived SESM is how the patient views their ability to
implement behaviors to prevent, recognize, and relieve symptoms (White et al., in press).
Definition of the concept is necessary for research and guides future intervention development.
The concept analysis described the concepts of self-efficacy and symptom management.
These concepts have been analyzed separately in nursing literature; however, this is the first
analysis of the concept of SESM. Constructed cases, both a model and a contrary case,
demonstrated how the concept is operationalized in patients with cancer. The attributes of SESM
are cognitive processes, affective processes, motivation, confidence, competence, and awareness.
Antecedents are the presence of symptoms, performance accomplishment, verbal persuasion and
presence of threat or fear. Consequences of perceived SESM are symptom relief, health status,
the cost of care, quality of life (QOL), and behavior performance.
Chapter III presented an integrative literature review that examined self-efficacy and
management of symptoms and symptom distress in patients with cancer. The review included 20
articles, including intervention and descriptive research, one integrative review and one theory
paper. Only three of the 20 publications described self-efficacy and symptom management in
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HSCT patients; all three were studies conducted with patients who were at one year or longer
post-HSCT (Bergkvist et al., 2015; Hochhausen et al., 2007; Wu et al., 2012). Results of the
review showed a relationship exists between self-efficacy and symptoms in cancer patients, with
high self-efficacy leading to better symptom management and lower symptom distress.
The concept analysis presented in Chapter II and the literature review in Chapter III
supported and expanded upon the theoretical foundations and conceptual relationships discussed
in Chapter I. Chapters II and III also provided the foundation for the research presented in
Chapters IV and V. The concept analysis and literature review results established the conceptual
definition and the presence of a relationship between self-efficacy and symptoms in cancer
patients and HSCT patients one year or more post-transplant. What remained unknown was the
relationship between these concepts in the HSCT population within the first 30 days posttransplant. Chapter IV described the longitudinal, descriptive research study methodology and
results and Chapter V describes the patient’s perspective of SESM.
The study purpose was to describe the changes over time and relationships among SESM,
symptom distress, and the outcomes of physical function and length of stay during the acute
phase, or 30 days post-HSCT. The specific aims were:
1. Explore the concept of SESM from the patient’s perspective at baseline and 30 days.
2. Determine the changes over time in SESM, symptom distress, and physical function.
3. Examine the relationships among SESM, symptom distress, and physical function.
4. Determine if the relationships among SESM and length of stay, readmission rates, and
functional status varies depending on the level of symptom distress.
Demographic and clinical data were similar to what was found in other studies in HSCT
patients (Bevans, Mitchell, & Marden, 2008; Cohen et al., 2012; Wu et al., 2012). Symptom
experience and timing was also comparable to those reported in other studies (Anderson et al.,
2007, Cohen et al., 2012). For the first aim, significant changes over time were found in all
variables: SESM, symptom distress and physical function. Significant relationships were found
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among symptom distress, SESM, and physical function at all time points for the second aim. For
the final aim, physical function and SESM varied depending on the level of symptom distress at
day 15. Overall, higher SESM was associated with fewer symptoms and increased physical
function while less symptom distress was associated with increased physical function and SESM.
This study established a relationship between SESM and symptom distress, specifically during
the phase of HSCT when symptom distress is highest.
Chapter V described the meaning of SESM from the perspective of patients both before
and after HSCT. Themes of confidence, responsibility and caring for mind, body, and spirit were
described by study participants along with subthemes of self-confidence, confidence in others,
confidence and symptom level, vigilance, self-advocacy, and normalcy. These themes related to
the findings of the concept analysis such as confidence (self and others), cognitive processes
(self-advocacy), affective processes and motivation (mind, body, spirit), awareness (vigilance),
the presence of symptoms (symptom level), and symptom relief (normalcy). These findings
validate the concept analysis and give voice to the patient’s experience.
Practice and Research Implications
The presence of SESM in cancer and HSCT patients is vital for optimal patient outcomes.
Because a relationship exists between SESM, symptom distress, and physical function,
enhancement of SESM has the potential to reduce symptom distress and improve patient
outcomes. SESM can be learned, which creates an opportunity for nursing intervention.
SESM should be assessed at the earliest opportunity after treatment for cancer is begun.
Instruments have been developed and tested to assess self-efficacy in survivors with breast cancer
(Champion et al., 2013), SESM in patients with breast cancer (Liang, Wu, Kuo, & Lu, 2015) and
for self-efficacy for fatigue management (Hoffman et al., 2011). For other patient populations or
general symptom management, assessment can be done briefly and efficiently with the PatientReported Outcomes Measurement Information System (PROMIS) self-efficacy scales for
managing chronic conditions using the instrument short forms or computer adaptive testing
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(Patient-Reported Outcomes Measurement Information System, 2015). SESM can be assessed
using the Self-efficacy for Managing Symptoms Short Form 8a (Figure 1) and Self-efficacy for
Managing Medications and Treatments Short Form 8a (Figure 2). Computer adaptive testing
delivers questions based on patient’s response to a previously administered question.
Educational or problem-solving strategies that are patient specific can be developed using
results from the assessment. For example, if patients respond that they are not confident in listing
their medication names or schedule, remembering to take medications as prescribed, or finding
the information they need to manage symptoms, a patient-centered intervention can be developed.
If persons respond that they are not confident in understanding the differences between symptoms
and side effects of medication, education can be tailored that contrasts signs and symptoms of
potential complications of treatment (i.e. fever, infection, mucositis) with the adverse effects of
the persons’ medications. The assessment finding would guide the multidisciplinary intervention,
which will be targeted toward the patient need, whether it be coaching, education, or finding
resources. Multi-disciplinary involvement is critical as needs for SESM include expertise from
nurses as well as pharmacists, physical therapists, social workers, case managers, or cognitive
behavioral therapists. Administration of these interventions should occur when symptom burden
or distress is low, as the presence of high physical and psychological symptom distress is a barrier
to SESM (White, Kupzyk, Berger, Cohen, & Bierman, in process; Wu et al., 2012).
SESM plays a key role in outcomes for patients in all stages of treatment for cancer,
including HSCT. This body of work lays the foundation for assessment and development of
patient-centered intervention development. Future research should test the outcomes of these
interventions in relation to the presence of symptom distress, physical functional status, use of
health care resources, and overall QOL.
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Figure 1: Self-efficacy for Managing Symptoms – Short Form 8a
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Figure 2: Self-efficacy for Managing Medications and Treatments – Short Form 8a
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APPENDIX G
Self-efficacy for Symptom Management in Stem Cell Transplant Patients
Demographic and Clinical Data Collection Tool
(Collected from Electronic Medical Record)
Subject ID _________________________
1. Age__________________________________________
2. Gender

M /F

3. Race __________________________________________
4. Ethnicity _______________________________________
5. Employment status
a. Full time / Part time / Retired / Disability / Unemployed
b. If unemployed or disability – prior employment ___________________
6. Marital status Married / Single / Widowed / Divorced
7. Family Caregiver Y / N
8. Primary Disease _________________________________
Location ________________________________
Stage ___________________________________
9. Transplant type (circle one)
a. Autologous / Related Allogeneic / Unrelated Allogeneic / Cord Blood
10. Conditioning Regimen ______________________________
11. Comorbid conditions Comorbidity Score ________________
a. __________________________________________
b. _________________________________________
c. __________________________________________
12. Length of stay for transplant admission ____________________
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APPENDIX I

PROMIS Item Bank v1.0 - Self-Efficacy for Managing Symptoms
Please rate your CURRENT level of confidence in managing your health conditions by
filling in one box per row. Consider all of your health conditions and all of your symptoms
in your responses to the questions. If a question is not something you have experienced,
choose an answer based on similar experiences.

CURRENT level of
confidence…

SEMSX001

SEMSX002

SEMSX003

SEMSX004

SEMSX005

I can make a
moderate reduction
in my symptoms
.................................
I can reduce my
symptoms to my
satisfaction
.................................
I can control my
symptoms by taking
my medications
.................................
I can control my
symptoms by using
methods other than
taking medication
(for example:
relaxation exercises,
distraction).
.................................
I can do something
to reduce my

I am

I am

not at all
confident

a little
confident

I am
somewhat
confident

I am

I am











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5

quite
very
confident confident
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symptoms when
they worsen
.................................

SEMSX006

SEMSX007

SEMSX008

SEMSX009

SEMSX010

SEMSX011

SEMSX012

I can do something
to prevent my
symptoms from
worsening
.................................
I can manage
unexpected or new
symptoms
.................................
I can manage my
symptoms when I
am at home
.................................
I can manage my
symptoms in a
public place
.................................
I can manage my
symptoms during
my daily activities
.................................
I can work with my
doctor to manage
my symptoms
.................................
I can manage my
symptoms as well as
other people with
symptoms like mine
.................................











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5
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SEMSX013

SEMSX014

I can keep my
symptoms from
interfering with my
sleep
.................................
I can keep my
symptoms from
interfering with
relationships with
friends and family.

CURRENT level of
confidence…

SEMSX015

SEMSX016

SEMSX017

I can keep my
symptoms from
interfering with the
work I need to do
...............................
I can keep my
symptoms from
interfering with my
recreational
activities
...............................
I can keep my
symptoms from
interfering with my
personal care
...............................











1

2

3

4

5











1

2

3

4

5

I am not
at all
confident

I am a
little
confident

I am
somewhat
confident

I am

I am

quite
confident

very
confident











1

2

3

4

5










1

2

3

4











1

2

3

4

5

5
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SEMSX018

SEMSX019

SEMSX020

SEMSX021

SEMSX022

SEMSX023

SEMSX024

SEMSX025

I can enjoy things,
despite my
symptoms
...............................
I can still
accomplish most of
my goals in life,
despite my
symptoms
...............................
I can live a normal
life, despite my
symptoms
...............................
I can be physically
active, despite my
symptoms
...............................
I can maintain my
sense of humor,
despite my
symptoms
...............................
I can recognize
when my
symptoms change
...............................
I know what to do
when my
symptoms worsen
...............................
I can rely on my
judgment to
manage my











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5
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symptoms, even
when others
disagree with me
...............................

SEMSX026

SEMSX027

SEMSX028

I can manage my
symptoms when I
am in an unfamiliar
place
...............................
I can find the
information I need
to manage my
symptoms
...............................
I can manage my
symptoms when I
am tired
...............................











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5
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APPENDIX J

PROMIS Item Bank v1.0 - Self-Efficacy for Managing Medications and
Treatments
Please rate your CURRENT level of confidence in managing your medications and
other treatments by filling in one box per row. Consider all of your health conditions
and all of your symptoms in your responses to the questions. If a question is not
something you have experienced, choose an answer based on similar experiences.
CURRENT level of
confidence…

SEMMT001

SEMMT002

SEMMT003

SEMMT004

SEMMT005

SEMMT006

I can take several
medications on
different schedules
................................
I can remember to
take my medication
as prescribed
................................
I know when and
how to take my
medications
................................
I can fit my
medication
schedule into my
daily routine
................................
I can follow
directions when my
doctor changes my
medications
................................
I can manage my
medication without

I am

I am

I am

I am

a little
confident

I am
somewhat
confident

not at all
confident

quite
confident

very
confident











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5
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help.
................................

SEMMT007

SEMMT008

SEMMT009

SEMMT010

SEMMT011

SEMMT012

SEMMT013

I can get help when
I am not sure how
to take my
medicine
................................
I can remember to
refill my
prescriptions
before they run out
................................
I can remember to
take my
medications when
there is no one to
remind me
................................
I can list my
medications,
including the doses
and schedule
................................
I can actively
participate in
decisions about my
treatment
................................
I can find
information to
learn more about
my treatment
................................
I can use my own
judgment regarding
treatment











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5

152

alternatives
(including not
having treatment)
................................

SEMMT014

I can work with my
doctor to choose
the treatment that
seems right for me
................................

CURRENT level of
confidence…

SEMMT015

SEMMT016

SEMMT017

I know what to do
when my
medication refill
looks different than
usual
.................................
I know what to do if
I forget to take my
medication(s)
.................................
I can use technology
to help me manage
my medication and
treatments (for
example: to get
information, avoid
side-effects,
schedule reminders)
.................................











1

2

3

4

5

I am

I am

I am not
at all
confident

I am a
little
confident

I am
somewhat
confident











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5

quite
very
confident confident
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SEMMT018

SEMMT019

SEMMT020

SEMMT021

SEMMT022

SEMMT023

SEMMT024

I can continue my
treatment when
traveling
.................................
I can take my
medication when I
am working or away
from home
.................................
I can take my
medicine even if it
causes mild side
effects
.................................
I understand the
difference between
my symptoms and
medication side
effects
.................................
I can continue my
treatment when I
am not feeling well
.................................
I can take my
medication when
there is a change in
my usual day
(unexpected things
happen)
.................................
I can figure out what
treatment I need
when my symptoms











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5











1

2

3

4

5
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change
.................................

SEMMT026

SEMMT027

I can follow a full
treatment plan
(including
medication, diet,
physical activity)
.................................
I can travel to my
local pharmacy to
fill my prescriptions
.................................











1

2

3

4

5











1

2

3

4

5
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